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Preimplantation  genetic  diagnosis  (PGD),  also  known  as  preimplantation  genetic 
testing  (PGT),  is offered  to  couples with  a high  risk of having  a  child with  a  severe 
genetic  disorder  or  with  an  increased  risk  of  miscarriages  due  to  a  structural 
chromosomal  rearrangement.  The  use  of  PGD  provides  couples  the  opportunity  to 












PGD  was  introduced  in  the  Netherlands  in  1995  and  the  requests  for  PGD  are 
increasing since, starting from less than 50 referrals in the first years to more than 500 
referrals  per  year  at  the  moment.2  The  Maastricht  University  Medical  Center+ 
(MUMC+)  is  the only center  licensed  to offer PGD services. Since 2008, patients can 
also get general  information about PGD and undergo  the  IVF/ICSI procedure  in  the 
University  Medical  Center  Utrecht,  University  Medical  Center  Groningen  or  the 
Amsterdam University Medical Center. Together the MUMC+ and the three so‐called 
transport  centers  have  united  to  form  PGD  the  Netherlands.  The  PGD  the 
Netherlands’  activities  are  coordinated  by  the  PGD  Medical  Coordinator  who  is 
allocated  at  the MUMC+.  The  PGD Medical  Coordinator  is  supported  by MUMC+’s 
multidisciplinary  PGD  working  group  consisting  of  clinical  geneticists,  laboratory 
geneticists,  gynecologists,  embryologists,  ethicists  and  laboratory  technicians.  If 
necessary,  several  medical  specialists  or  professionals,  for  instance  psychologists, 
oncologists  or  neurologists,  can  be  consulted.  Each  of  the  transport  centers  has  a 
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For  PGD,  oocytes,  retrieved  from  the  ovary  after  ovarian  hyperstimulation,  are 
fertilized  either  by  conventional  IVF  or  intracytoplasmic  sperm  injection  (ICSI). 
Traditionally, on day  three after  fertilization one blastomere  (or  incidentally  two)  is 
biopsied  from  the  cleavage  stage  embryo  by  creating  a  hole  in  the  zona  pellucida 
using a  laser. The biopsied blastomere  is  tested  for  the  familial genetic disorder.8‐10 
Recently,  a  new  biopsy method  was  introduced,  called  trophectoderm  biopsy  (TE 
biopsy). TE biopsy  is done at day  five or six after  fertilization, when the embryo has 





steps  into  the PGD era.12 The use of  this  technique enabled  the selection of  female 
embryos which were not at increased risk of developing the genetic disease. FISH, and 
later  array‐CGH,  was  used  for  the  evaluation  of  chromosomal  imbalances.8  The 
application of PCR techniques on single cells eventually made it possible to select for 
monogenic  and mitochondrial disorders.9,13 PCR based PGD analyses consists of either 
direct  mutation  analyses  in  combination  with  at  least  one  microsatellite  marker 
flanking  the  gene  or  indirect  analyses  with  multiple  microsatellite  markers.10,14,15 
Mutation detection  is performed using  fragment  length  (insertions/deletions) or  the 
double  allele  amplification  refractory mutation  systems  (D‐ARMS)  technique  (single 
base  pair  changes).  Mitochondrial  DNA  mutations  require  a  semi‐quantitative 
test.9,10,14,15 Nowadays, Next Generation  Sequencing  (NGS)  is used preferentially  for 
the detection of chromosomal abnormalities as well as for the analysis of monogenic 
disorders. The upcoming NGS based SNP‐haplotyping will probably be feasible for all 
indications  in  one  test,  i.e.  the  OnePGT  test,  thereby  enabling  PGD  for  combined 
monogenic  and  chromosomal  anomalies.  Aneuploidy  screening  is  currently  not 
performed in the Dutch PGD clinics.14 
 
At  the  time  of  the  genetic  analysis,  the  development  of  the  embryos  is  closely 
monitored  in  the  IVF  lab.  In  case  of  biopsy  on  day  three,  preferably  one  embryo, 
without the target condition in the biopsied cell(s), is transferred in utero on day three 





In  2009  the  Ministry  of  Public  Health,  Welfare  and  Sport  decided  that  all  new 
indications  for PGD  should be evaluated by an  independent  so‐called PGD National 
Indications Committee. This decision followed a nationwide discussion about offering 
PGD  for  late‐onset disorders with  incomplete penetrance,  such as hereditary breast 
and ovarian cancer, and the accompanying questions about the moral acceptability of 
certain  indications  for  PGD.3  The  PGD  National  Indications  Committee  consists  of 
delegates  from  the  national  association  of  clinical  geneticist  and  the  national 
association  of  gynecologists,  ethicists  and  a  representative  of  the  patient 
organizations.  This  committee  evaluates whether  a  new  indication  for  PGD meets 
legal  and  ethical  standards,  as  formulated  in  the  “Embryowet”  and  in  the  PGD 
guidelines as published in the Staatscourant.4  
 
The  increasing number of  referrals  for PGD might be due  to  the  improved  technical 
possibilities  to diagnose  genetic disorders  and  to  the  growing  knowledge of health 
care providers and  the public about genetics  in general and also about PGD.5,6 Such 
growing knowledge also  increases  the  involvement of Dutch  citizens, as well as  the 
government,  in  discussions  about  the  introduction  of  new medical  techniques  and 
treatments like PGD. While there is a broad political and societal support for PGD, the 
use of such a new and  innovative technique also raises questions with regard to the 






the moral acceptability of  certain  indications  for PGD,  i.e.  less penetrant mutations 
and highly variable disorders.  
The PGD procedure 
The  combination  of  techniques  used  for  PGD  contributes  to  the  complexity  of  the 
treatment,  starting with  in‐vitro  fertilization  (IVF)  treatment, which  is  necessary  to 
obtain  preimplantation  embryos,  followed  by  a  biopsy, which  is  necessary  for  the 
genetic analysis.  
 




Preimplantation genetic diagnosis (PGD), also known as preimplantation genetic 
testing (PGT), is offered to couples with a high risk of having a child with a severe 
genetic disorder or with an increased risk of miscarriages due to a structural 
chromosomal rearrangement. The use of PGD provides couples the opportunity to 
know the genetic status before the embryo is implanted in the uterus and thus to 
select embryos without the genetic disorder running in their family or with the familial 
unbalanced karyotype. Therewith PGD is a fair reproductive option for couples at risk 
in addition to the spectrum of already existing reproductive choices such as prenatal 
testing, gamete donation, acceptance of the risk or refraining from having children. 
Contrary to prenatal testing, PGD makes it possible to avoid the selective abortion of 
fetuses affected with a hereditary disorder.1 
 
PGD is considered to be a complex medical intervention associated with human 
reproduction. It is therefore a delicate topic for both medical experts and society. This 
thesis is about the safety of PGD. 
PGD in t  N therla s 
PGD was introduced in the Netherlands in 1995 and the requests for PGD are 
increasing since, starting from less than 50 referrals in the first years to more than 500 
referrals per year at the moment.2 The Maastricht University Medical Center+ 
(MUMC+) is the only center licensed to offer PGD services. Since 2008, patients can 
also get general information about PGD and undergo the IVF/ICSI procedure in the 
University Medical Center Utrecht, University Medical Center Groningen or the 
Amsterdam University Medical Center. Together the MUMC+ and the three so-called 
transport centers have united to form PGD the Netherlands. The PGD the 
Netherlands’ activities are coordinated by the PGD Medical Coordinator who is 
allocated at the MUMC+. The PGD Medical Coordinator is supported by MUMC+’s 
multidisciplinary PGD working group consisting of clinical geneticists, laboratory 
geneticists, gynecologists, embryologists, ethicists and laboratory technicians. If 
necessary, several medical specialists or professionals, for instance psychologists, 
oncologists or neurologists, can be consulted. Each of the transport centers has a 
comparable multidisciplinary PGD team, but the MUMC+’s PGD working group is 










termination,  the burden of  the  IVF  treatment and  the  relatively  low pregnancy  rate 
when compared to natural conception, are taken into account by the couples.16 
 
Studies on  the  reproductive decision‐making process  in  couples with a high  risk on 
offspring with HBOC report on additional disease specific arguments  for and against 
PGD. An important issue for women with a high risk on HBOC is the safety of the IVF 
procedure  for  themselves  (especially  the  hormonal  stimulation)  and  the  time  to 
pregnancy, since the time to pregnancy affects the timing of prophylactic surgery.3 A 









child,  can  take   months  to even  years. Couples may experience  this period  as  very 
stressful and intensive.19 Part of the couples have a complex reproductive history with 
infertility,  multiple  miscarriages  and/or  pregnancy  terminations,  have  an  affected 
child at home or are affected with or  in  the prodromic phase of a genetic disorder 








to  the uterus usually  takes place several weeks after  the  IVF procedure,  resulting  in 









PGD was  initially offered  to  couples with a high  risk of having a  child with either a 
severe, early onset or  lethal, monogenic, mitochondrial or chromosomal disorder or 
with  a  high  risk  of  miscarriages  due  to  a  structural  chromosomal  abnormality. 
Nowadays,  PGD  is  also  approved  for  late‐onset  disorders,  or  disorders  with 




A  common  alternative  for  PGD  is  to  pursue  a  natural  conception  and  choose  for 
invasive (chorionic villus sampling or amniotic fluid sampling) or non‐invasive prenatal 
testing  (NIPT).16 When  the  fetus  is affected,  the couple can decide  to  terminate  the 
pregnancy. NIPT  for gender determination  (performed  in  case of a  familial X‐linked 
disorder),  aneuploidy  detection  and  for  detection  of  large  chromosomal 
rearrangements  is available. NIPT  is a  safe method and  can now be offered  from a 
pregnancy  duration  of  11 weeks  gestational  age.  Current NIPT  diagnosis  has  to  be 
confirmed by invasive prenatal testing as the positive predictive value is not 100%. In 
the nearby  future, couples will probably get  the opportunity  to opt  for non‐invasive 
prenatal diagnosis (NIPD) for monogenic disorders.17  It is still an open question if and 
when NIPT/NIPD  can be  applied  reliably  very early  in pregnancy. Other options  for 
couples with  a  high  risk  of  transmitting  a  genetic  disease  to  their  offspring  are  to 
pursue a natural conception without any genetic testing, to use donor semen or donor 
oocytes or  to apply  for adoption. Some couples eventually end up without  fulfilling 
their desire to have children. 
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Gen ral introduction 
Preimplantation genetic diagnosis (PGD), also known as preimplantation genetic 
testing (PGT), is offered to couples with a high risk of having a child with a severe 
genetic disorder or with an increased risk of miscarriages due to a structural 
chromosomal rearrangement. The use of PGD provides couples the opportunity to 
know the genetic status before the embryo is implanted in the uterus and thus to 
select embryos without the genetic disorder running in their family or with the familial 
unbalanced karyotype. Therewith PGD is a fair reproductive option for couples at risk 
in addition to the spectrum of already existing reproductive choices such as prenatal 
testing, gamete donation, acceptance of the risk or refraining from having children. 
Contrary to prenatal testing, PGD makes it possible to avoid the selective abortion of 
fetuses affected with a hereditary disorder.1 
 
PGD is considered to be a complex medical intervention associated with human 
reproduction. It is therefore a delicate topic for both medical experts and society. This 
thesis is about the safety of PGD. 
PGD in the Netherlands 
PGD was introduced in the Netherlands in 1995 and the requests for PGD are 
increasing since, starting from less than 50 referrals in the first years to more than 500 
referrals per year at the moment.2 The Maastricht University Medical Center+ 
(MUMC+) is the only center licensed to offer PGD services. Since 2008, patients can 
also get general information about PGD and undergo the IVF/ICSI procedure in the 
University Medical Center Utrecht, University Medical Center Groningen or the 
Amsterdam University Medical Center. Together the MUMC+ and the three so-called 
transport centers have united to form PGD the Netherlands. The PGD the 
Netherlands’ activities are coordinated by the PGD Medical Coordinator who is 
allocated at the MUMC+. The PGD Medical Coordinator is supported by MUMC+’s 
multidisciplinary PGD working group consisting of clinical geneticists, laboratory 
geneticists, gynecologists, embryologists, ethicists and laboratory technicians. If 
necessary, several medical specialists or professionals, for instance psychologists, 
oncologists or neurologists, can be consulted. Each of the transport centers has a 
comparable multidisciplinary PGD team, but the MUMC+’s PGD working group is 








procedure,  is  still  lacking.26 Therefore  there  is an urge  for  careful evaluation of  the 
health of children born after PGD. One of the main outcome measures evaluated  in 






rapid  catch‐up  growth  in  their  early  years  of  life  which  can  probably  lead  to  an 
increased risk of cardiovascular disease later in life.31,32 A study in a Belgian cohort of 
2‐year‐old children born after PGD reports similar growth when compared to children 
born after  IVF/ICSI.33 Further evaluation of  the growth of  (older) children born after 




as  ‘a  state  of  complete  physical, mental  and  social well‐being  and  not merely  the 
absence of disease or infirmity’.34 Both mental and social well‐being can be influenced 
by the physical health of a person, but also by the person’s environment. Growing up 
in  a  family with  a  family member  (parent or  sibling) with  a  severe  illness, which  is 
common  for  children  born  after  PGD,  can  influence  a  child’s well‐being.35  Children 









per  child.  Thus,  their  overall  chance on  a  liveborn  child  is  probably  lower  than  for 
couples who try to conceive naturally.  
 
Information  about  the  expected  pregnancy  course  is  of  great  importance  for  both 
health care providers as well as for couples opting for PGD. Studies on obstetric and 
perinatal outcome of pregnancies  following PGD  treatment are, however,  scarce.  In 








important.  The  European  Society  of Human  Reproduction  and  Embryology  (ESHRE) 
repeatedly reports on the cumulative PGD results of all the affiliated PGD centers. In 














many  people.  This  concern  is  in  line with  the Developmental Origin  of Health  and 
Disease  (DOHaD)  hypothesis  discussing  the  link  between  early  embryonic 
development  and  health  later  in  life.25  This  hypothesis  states  that  the  risk  for  the 
development of diseases later in life finds its origin during early development and can 
be negatively  influenced by environmental stressors.25 This  is especially  relevant  for 
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testing, gamete donation, acceptance of the risk or refraining from having children. 
Contrary to prenatal testing, PGD makes it possible to avoid the selective abortion of 
fetuses affected with a hereditary disorder.1 
 
PGD is considered to be a complex medical intervention associated with human 
reproduction. It is therefore a delicate topic for both medical experts and society. This 
thesis is about the safety of PGD. 
PGD in the Netherlands 
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Amsterdam University Medical Center. Together the MUMC+ and the three so-called 
transport centers have united to form PGD the Netherlands. The PGD the 
Netherlands’ activities are coordinated by the PGD Medical Coordinator who is 
allocated at the MUMC+. The PGD Medical Coordinator is supported by MUMC+’s 
multidisciplinary PGD working group consisting of clinical geneticists, laboratory 
geneticists, gynecologists, embryologists, ethicists and laboratory technicians. If 
necessary, several medical specialists or professionals, for instance psychologists, 
oncologists or neurologists, can be consulted. Each of the transport centers has a 
comparable multidisciplinary PGD team, but the MUMC+’s PGD working group is 
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‐ Do  children  born  after  PGD  have  a  higher  risk  for  congenital malformations  or 
adverse perinatal outcomes?  
  The perinatal  results of all  children born after PGD between 1995 and 2014 are 





growth  and  health  of  5‐year‐old  children  born  after  PGD  compared  to  children 




Finally,  chapter  6,  is  a  general  discussion  including  all  study  results  and  possible 
impact for reproductive practice.  
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with  or  without  ICSI  to  obtain  embryos  for  genetic  analysis.  Blastomeres  or 





It  is  hypothesized  that  assisted  reproductive  technologies,  especially more  invasive 
techniques like ICSI, increase the risk on birth defects.3,4 The need for embryo biopsy 




and  children  born  after  PGD  did  not  report  a  higher  rate  of  major  congenital 
malformations when compared  to  IVF‐ICSI children.6,7‐12 The  results of  these studies 
raise concerns about adverse perinatal and neonatal outcome,  like prematurity rate, 
the  incidence of  low and very  low birth weight as well as  the  incidence of perinatal 
mortality.  However,  the  reported  data  are  derived  from  only  one  large  and  three 




This  study  presents  mostly  prospectively  collected  data  concerning  the  perinatal 































We  found no evidence  that PGD  treatment  increases  the risk on congenital malformations or 
adverse perinatal outcome. 
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embryo  transfer,  gravidity,  parity,  number  of  previous  IVF/PGD  cycles  per  couple, 
whether pregnancy was derived from a fresh or frozen/ thawed embryo, after usage 
of  IVF  or  ICSI  and  PCR,  FISH  or  array‐CGH  for  analysis,  number  of  blastomeres 
biopsied,  number  of  transferred  embryos,  number  of  live  born  children,  gender, 
singleton  or multiple,  PGD  indication, major  and minor malformations,  still  births, 
pregnancy  terminations, misdiagnosis,  pre‐  and  postnatal  genetic  testing,  term  at 
delivery, birth weight, perinatal mortality and hospital admissions.  
Statistics  
SPSS  version  22  (IBM  SPSS,  Chicago  IL)  was  used  for  descriptive  statistics.  The 
categorical data are presented as proportions. The continuous data are presented as 
mean and standard deviation. Further, z‐scores were calculated for birth weight of all 
singletons  by  normalizing  the  weight  of  each  child  using  the  mean  weight  with 










a  pregnancy  duration  of  more  than  12  weeks.  A  miscarriage  is  defined  as  the 
spontaneous loss of a pregnancy before 20 completed weeks of gestational age. A still 
birth is defined as death before the complete expulsion or extraction from its mother, 
at or  after 20  completed weeks of  gestational  age. Deliveries before 37  completed 
weeks of gestation are defined premature and a child  is born very premature when 
delivered before 32 weeks of gestational age. Low birth weight  is defined as a birth 







and  forty  IVF‐ICSI  treatments were performed  in  the Maastricht University Medical 
Centre+  (MUMC+), 161  in  the University Medical Centre Utrecht  (UMCU), 36  in  the 
University Medical  Centre  Groningen  (UMCG)  and  two  in  the  Amsterdam Medical 
Centre  (AMC).  The  latter  three  IVF  departments  are  PGD  transport  centers.13  All 




according  to  local  protocols,  as  well  as  the  procedures  for  IVF  or  ICSI,  but  they 




years  of  PGD.  Blastomeres  were  analysed  using  PCR  in  case  of  monogenetic  or 
mitochondrial  conditions  and  FISH  analysis  in  case  of  chromosomal  abnormalities. 
Recently,  array‐CGH  has  replaced  the  FISH  technique.  Embryos  were  cultured  in 
individual drops of medium where  the development was  recorded. On day  three or 














Preimplantation genetic diagnosis (PGD) offers couples at high risk for transmitting a 
genetic disease to their offspring an alternative to prenatal diagnosis or may enhance 
their probability of an ongoing pregnancy if one of the parents is carrier of a structural 
chromosomal abnormality.1 Couples opting for PGD have to go through IVF treatment 
with or without ICSI to obtain embryos for genetic analysis. Blastomeres or 
trophectoderm (TE) cells for diagnosis are procured through embryo biopsy and 
analysed by either polymerase chain reaction (PCR), fluorescence in situ hybridization 
(FISH) or array-comparative genomic hybridization (array-CGH) in order to determine 
a specific genetic defect or a chromosomal abnormality.2 
 
It is hypothesized that assisted reproductive technologies, especially more invasive 
techniques like ICSI, increase the risk on birth defects.3,4 The need for embryo biopsy 
makes PGD an even more invasive procedure than IVF(-ICSI) treatment alone. 
Consequently, the safety of PGD is an issue that needs constant scrutinizing, the more 
since the number of pregnancies after PGD is increasing over the years.5 Since the first 
PGD treatment was performed in the early 1990s, clinical studies on PGD pregnancies 
and children born after PGD did not report a higher rate of major congenital 
malformations when compared to IVF-ICSI children.6,7-12 The results of these studies 
raise concerns about adverse perinatal and neonatal outcome, like prematurity rate, 
the incidence of low and very low bir h weight as well as the incidence of perinatal 
mortality. However, the reported data are derived from only one large and thre  
small cohorts whic  mak s collection of more data de irable. Al o, thes  cohorts 
mostly contain data on pregn cies and children bor  after preimplantation genetic 
screening (PGS), and thus include couples with a history of infertility. 
 
This study presen s m stly prospectively collected data conc rning the perinatal 
outcome of all PGD pregnancies in the Netherlands b tween 1995 a d 2014. PGS 
pregnancies are not included. In view of earlier reported concerns and accompanying 
importance for patients and health care providers the aim of this study is to establish 
th  safety of PGD in the Neth rlands nd to contribute to the justification of PGD as a 
tool in heritabl  diseas  prevention. We focus n the congeni al malform tion ra e 


































































Major malformations were  seen  in nine of  the 364  live born  children  (2.5%)  (Table 
3.2). Four of these children showed multiple congenital anomalies (MCA): two had a 
chromosomal  abnormality  (one  singleton  had  trisomy  21  and  one  of  a  twin  had 
trisomy 9 mosaicism), one child presented with an atrial septum defect grade  II, an 
orofacial  cleft,  and  a  hydronephrosis  and  the  fourth  had  an  unilateral  facial  nerve 





Perinatal mortality  denotes  fetal  or  neonatal  death  during  the  second  term  of  the 
pregnancy (after 20 weeks), during delivery or until 7 days after the date of birth.19 
Literature overview 




This  study was  approved by  the  local Medical  Ethics Committee. Written  informed 
consent was obtained from all participants before their enrolment in the study. 
Results 
The  characteristics of  the  couples,  treatments and  children are  shown  in Table 3.1. 




Four  hundred  and  thirty‐nine  clinical  pregnancies  resulted  in  366  children.  Two 
children were  lost to  follow‐up and excluded  from analyses. Thirteen percent of the 
pregnancies were multiple pregnancies and 28% of the live born children were part of 
a twin or triplet. In 85.5% of the multiple pregnancies, two embryos were transferred. 
There  was  a  decline  in  the  double  embryos  transfer  rate  and  the  occurrence  of 
multiple pregnancies over time.  
 
The  largest  proportion  of  couples  (39%)  opted  for  PGD  because  of  an  autosomal 








Preimplantation genetic diagnosis (PGD) offers couples at high risk for transmitting a 
genetic disease to their offspring an alternative to prenatal diagnosis or may enhance 
their probability of an ongoing pregnancy if one of the parents is carrier of a structural 
chromosomal abnormality.1 Couples opting for PGD have to go through IVF treatment 
with or without ICSI to obtain embryos for genetic analysis. Blastomeres or 
trophectoderm (TE) cells for diagnosis are procured through embryo biopsy and 
analysed by either polymerase chain reaction (PCR), fluorescence in situ hybridization 
(FISH) or array-comparative genomic hybridization (array-CGH) in order to determine 
a specific genetic defect or a chromosomal abnormality.2 
 
It is hypothesized that assisted reproductive technologies, especially more invasive 
techniques like ICSI, increase the risk on birth defects.3,4 The need for embryo biopsy 
makes PGD an even more invasive procedure than IVF(-ICSI) treatment alone. 
Consequently, the safety of PGD is an issue that needs constant scrutinizing, the more 
since the number of pregnancies after PGD is increasing over the years.5 Since the first 
PGD treatment was performed in the early 1990s, clinical studies on PGD pregnancies 
and children born after PGD did not report a higher rate of major congenital 
malformations when compared to IVF-ICSI children.6,7-12 The results of these studies 
raise concerns about adverse perinatal and neonatal outcome, like prematurity rate, 
the incidence of low and very low birth weight as well as the incidence of perinatal 
mortality. However, the reported data are derived from only one large and three 
small cohorts which makes collection of more data desirable. Also, these cohorts 
mostly contain data on pregnancies and children born after preimplantation genetic 
screening (PGS), and thus include couples with a history of infertility. 
 
This study presents mostly prospectiv ly collected data con erning the perinatal 
outcome of all PGD preg ancies in the Netherlands between 1995 and 2014. PGS 
pregnancies are not included. In view of earlier reported concerns and accompanying 
importance for patients and ealth care providers the aim of this study is to establish 
the safety of PGD in the Neth rland  and to contribute to the justification of PGD as a 
tool in heritable disease prevention. We focus on the congenit l malformation rat  
and addition lly report on misdiagnosis, b rth param ters and on perinatal m rtality 
















































































Five children  (1.4%) had a minor malformation. Ultrasound of  the neonatal spine  in 
two children with a sacral dimple showed closed vertebrae. Three children presented 
with  a  congenital  herniation:  two  twin  sisters  both  had  an  umbilical  hernia  and  a 






















































































































































a One case requested sex selection for boys: the 








































































































Preimplantation genetic diagnosis (PGD) offers couples at high risk for transmitting a 
genetic disease to their offspring an alternative to prenatal diagnosis or may enhance 
their probability of an ongoing pregnancy if one of the parents is carrier of a structural 
chromosomal abnormality.1 Couples opting for PGD have to go through IVF treatment 
with or without ICSI to obtain embryos for genetic analysis. Blastomeres or 
trophectoderm (TE) cells for diagnosis are procured through embryo biopsy and 
analysed by either polymerase chain reaction (PCR), fluorescence in situ hybridization 
(FISH) or array-comparative genomic hybridization (array-CGH) in order to determine 
a specific genetic defect or a chromosomal abnormality.2 
 
It is hypothesized that assisted reproductive technologies, especially more invasive 
techniques like ICSI, increase the risk on birth defects.3,4 The need for embryo biopsy 
makes PGD an even more invasive procedure than IVF(-ICSI) treatment alone. 
Consequently, the safety of PGD is an issue that needs constant scrutinizing, the more 
since the number of pregnancies after PGD is increasing over the years.5 Since the first 
PGD treatment was performed in the early 1990s, clinical studies on PGD pregnancies 
and children born after PGD did not report a higher rate of major congenital 
malformations when compared to IVF-ICSI children.6,7-12 The results of these studies 
raise concerns about adverse perinatal and neonatal outcome, like prematurity rate, 
the incidence of low and very low birth weight as well as the incidence of perinatal 
mortality. However, the reported data are derived from only one large and three 
small cohorts which makes collection of more data desirable. Also, these cohorts 
mostly contain data on pregnancies and children born after preimplantation genetic 
screening (PGS), and thus include couples with a history of infertility. 
 
This study presents mostly prospectively collected data concerning the perinatal 
outcome of all PGD pregnancies in the Netherlands between 1995 and 2014. PGS 
pregnancies are not included. In view of earlier reported concerns and accompanying 
importance for patients and health care providers the aim of this study is to establish 
the safety of PGD in the Netherlands and to contribute to the justification of PGD as a 
tool in heritable disease prevention. We focus on the congenital malformation rate 




              

























































































































































































































































for  admission were  prematurity,  (very)  low  birth weight  or  a  combination  of  both. 
Other reasons for admission directly after birth were blood glucose level monitoring, 




  Total  Singletons  Twins  Triplets 
Total  364  263(72.3%)  88 (24.2%)  13 (3.6%) 
   Term (mean in weeks)  38.6  39.2  36.3  34.1 
   Premature (<37 weeks)  63 (17.3%)  20 (7.6%)  35 (39.8%)  8 (61.5%) 
   Very premature (<32 weeks)  8 (2.2%)  ‐  8 (9.1%)  ‐ 
Birth weighta  N = 359  N = 262  N = 84  N = 13 
   Median in grams  3280  3462  2640  1900 
   Mean in grams (SD)  3199 (±699)  3450 (±533)  2554 (±610)  2148 (±696) 
   Mean z‐scoreb    0.17     
   Low birth weight (<2500 g)  52 (14.3%)  10 (3.8%)  31 (36.9%)  9 (69.2%) 
   Very low birth w. (<1500 g)  9 (2.5%)  1 (0.4%)  8 (9.5%)  ‐ 
Perinatal mortality  3 (0.7%)  1 (0.3%)  1 (0.3%)  1 (0.3%) 
Hospital admission  67 (18.4%)  36 (9.9%)  25 (6.9%)  8 (2.2%) 
   Low birth weight  28 (7.7%)       
   <37 weeks  34 (9.3%)       
adata on birth weight were missing of 5 children. b weight of the individual child minus the mean weight of 





Some  of  the  data  of  the  Dutch  PGD  population  are  presented  in  Table  3.4. 















heart  beat  on  ultrasound  showed  an  unbalanced  47,XX,+der(5)t(X;5)(q13;p14)mat 
karyotype.  The mother  was  a  46,X,t(X;5)(q13;p14)  carrier.  PGD  analysis  was  done 
using FISH (Table 3.2). 
Genetic testing, either, pre‐ or postnatal, was performed in 10% of the pregnancies. In 
53% of  the  cases  the  reason  for  testing was  confirmation of  the PGD diagnosis,  all 
were confirmed. Other indications were  miscarriages, an increased risk for a trisomic 






(reference:  Dutch  population  of  newborn  children  reported  by  PRN  Foundation, 
2013). The birth weight of almost half of  the children who were part of a  twin was 
considered to be  low or very  low, as was the birth weight of more than two third of 
the  children who were  part  of  a  triplet.  Only  one  singleton  had  a  very  low  birth 
weight. This child weighed 1490 grams and was born by selective caesarean section at 




at  23 weeks  and  4  days  gestational  age,  following  the miscarriage  of  his  sibling  at 




Preimplantation genetic diagnosis (PGD) offers couples at high risk for transmitting a 
genetic disease to their offspring an alternative to prenatal diagnosis or may enhance 
their probability of an ongoing pregnancy if one of the parents is carrier of a structural 
chromosomal abnormality.1 Couples opting for PGD have to go through IVF treatment 
with or without ICSI to obtain embryos for genetic analysis. Blastomeres or 
trophectoderm (TE) cells for diagnosis are procured through e bryo biopsy and 
analysed by either polymerase chain reaction (PCR), fluorescence in situ hybridization 
(FISH) or array-comparative genomic hybridization (array-CGH) in order to determine 
a specific genetic defect or a chromosomal abnormality.2 
 
It is hypothesized that assisted reproductive technologies, especially more invasive 
techniques like ICSI, increase the risk on birth defects.3,4 The need for embryo biopsy 
makes PGD an even more invasive procedure than IVF(-ICSI) treatment alone. 
Consequently, the safety of PGD is an issue that needs constant scrutinizing, the more 
since the number of pregnancies after PGD is increasing over the years.5 Since the first 
PGD treatment was performed in the early 1990s, clinical studies on PGD pregnancies 
and children born after PGD did not report a higher rate of major congenital 
malformations when compared to IVF-ICSI children.6,7-12 The results of these studies 
raise concerns about adverse perinatal and neonatal outcome, like prematurity rate, 
the incidence of low and very low birth weight as well as the incidence of perinatal 
mortality. However, the reported data are derived from only one large and three 
small cohorts which makes collection of more data desirable. Also, these cohorts 
mostly contain data on pregnancies and children born after prei plantation genetic 
screening (PGS), and thus include couples with a history of infertility. 
 
This study presents mostly prospectively collected data concerning the perinatal 
outcome of all PGD pregnancies in the Netherlands between 1995 and 2014. PGS 
pregnancies are not included. In view of earlier rep rted conc rns and accompanying 
importance for patients and health care p oviders the aim of this study is o establish 
th  s fety of PGD in the Netherl ds and to contribu e to the justification of PGD as a 
oo  in heritable disease prevention. We focus on the congenital malformation rate 

















Sex‐selection,  followed    by  the  transfer  of  a  female  embryo,  is  possible  for  carrier 
women  of  severe  X‐linked  conditions.  Corrected  for  sex‐selection  in  53  children,  a 




including  pregnancy  terminations  due  to  congenital malformations,  this was  3.3%. 
Other  PGD  studies  reported  a  comparable major malformation  rate  between  1.7% 
and 4.1%  in  live born children (Table IV) and conclude this to be equal to the risk on 
major malformations for IVF‐ICSI children. In a meta‐analysis Pandey et al. stated that 




period  between  2008  and  2012,  which  is  similar  to  the  prevalence  in  our  PGD 
cohort.18 Overall, the risk on major malformations  in children born after PGD seems 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































reimplant tion genetic diagnosis (PGD) offers couples at high risk for transmitting a 
genetic disease to their offspring an alternative t  pre atal diagnosis or may enhance 
their probability of an ngoing pregnancy if on  of the parents s carrier of a structural 
chromosomal abnor ality.1 Couples opting for PGD have to go through IVF treatment 
with or without ICSI to obtain embryos for genetic analysis. Blastomeres or 
trophec oderm (TE) cells for diagnosis are procured through m yo biopsy and 
analysed by either polymerase chain reacti n (PCR), fluorescence i  situ hybridization 
(FISH) or a ray-comparative genomic hybridization (ar ay-CGH) in order to determine 
a specific genetic defect or a chromosomal abnormality.2 
 
It is hypothesized that assisted reproductive technologies, especially more invasive 
t chniques like ICSI, increase the isk on birth defects.3,4 The need for embryo biopsy 
makes PGD an even more invasive proc dure than IVF(-ICSI) treatment alone. 
Consequently, the safety o  PGD is an issue that needs constant scruti izing, the more 
since the number of pregnancies after PGD is increasing over the years.5 Since the first 
PGD treatment was performed in the early 1990s, clinical studies on PGD pregnancies 
and children born after PGD did not report a higher rate of major congenital 
malformations when co pared to IVF-ICSI children.6,7-12 The results of these studies 
rais  concerns about adverse perinat l and neonatal outcome, like prematurity rate, 
the incidence of l w and very low birth weight as w ll a  he incidence of perinatal 
ortality. However, the reported data are derived from only one large and three 
small cohorts which makes collection of more data d sir ble. Al o, these cohorts 
mostly cont in data on pregnancies and children born fter preimplantation genetic 
screening (PGS), and thus include couples with a history of i fertility. 
 
This study pr sents mostly prospectively collected da a concerni g the pe inatal 
outcome of all PGD pregnancies in the Netherlands betw en 1995 and 2014. PGS 
pregnancies are not included. In view of arlier reported concern  and accompany ng 
importance for patients and health care providers the aim of this study is to establish 
the safety of PGD in the Netherlands and to contribute to the justification of PGD as a 
tool in heritable disease prevention. We focus  the congenital m lformation rate 








their PGD  cohort was 30%,  compared  to an  incidence of 3%  in naturally  conceived 
children.  Considering  the  possibly  higher  perinatal  risk  for  multiples  this  strongly 
supports the current SET policy. Since gestational age and birth weight in PGD children 
are  comparable  to  these parameters  in  IVF‐ICSI  children  it  could be  suggested  that 
PGD on itself is not an extra risk factor for adverse perinatal outcome.8,10,28  
 
We  report  one  unexplained  stillbirth  at  37  weeks  gestational  age.  Liebaers  et  al. 
reported the perinatal mortality rate to be higher  in PGD children (4.64%) compared 
to  ICSI  children.12 However, when  they  stratified  for multiples  the  increased  risk of 
perinatal death  in PGD and  ICSI singletons was comparable  (1.03%). A meta‐analysis 
by Lamont et al. of cohort and case‐control studies describes population based data 




The  incidence of hospital  admissions  is  lower  for our PGD  children  than previously 
described in PGD cohorts (Table 3.4). These admissions were not associated with the 
incidence of multiple pregnancies as previously seen in IVF‐ICSI cohorts. Explanations 
for  associations  found  in  these  latter  studies were  the higher  incidence of preterm 
birth and  low birth weight seen  in multiples. There seems  to be a  relation between 




Other  studies  reported  mostly  on  children  born  after  preimplantation  genetic 
screening  (PGS)  and  completed  their  cohort with data on  children born  after  PGD. 
Contrary to PGD, PGS is offered to couples with an IVF‐ICSI indication due to infertility 
and  is  considered  to  increase  the probability of achieving a pregnancy by excluding 
aneuploid  embryos.30 Our  prospectively  gathered  data  are  rather  complete  as  only 
two children were  lost to follow‐up. Our results  include data on perinatal events but 
also  pregnancy  terminations  before  the  perinatal  period,  loss  of  children  and 






aneuploidy  is  still  controversial.21  Liebaers  et  al.  reported  on  one  case  with  a 
chromosomal  abnormality,  in  their  PGD  cohort.12  Other  studies  do  not  report  on 
chromosomal  aberrations  in  their PGD  cohort. Bonduelle  et  al.  reported  a de‐novo 
chromosomal anomaly rate of 1.6%  in  ICSI offspring.22 Results of prenatal diagnostic 
tests in a large group of naturally conceived women aged 35 years and older, showed 
an  incidence of chromosomal abnormalities of 0.9%.23 Our results seem to be  in  line 
with  this,  however  the mean  age  of  the mothers  in  this  cohort was  slightly  lower 




fetal  karyotype  47,XX,+der(5)t(X;5)(q13;p14)mat.  This  case  has  been  extensively 

















studies on PGD and PGS show an evident  increase  in prematurity  in multiples when 
compared to singletons, as does the risk for low and very low birth weight (see for a 
summary Table 3.4). Our study distinguished very premature children from premature 




Preimplantation genetic diagnosis (PGD) offers couples at high risk for transmitting a 
genetic disease to their offspring an alternative to prenatal diagnosis or may enhance 
their probability of an ongoing pregnancy if one of the parents is carrier of a structural 
chromosomal abnormality.1 Couples opting for PGD have to go through IVF treatment 
with or without ICSI to obtain embryos for genetic analysis. Blastomeres or 
trophectoderm (TE) cells for diagnosis are procured through embryo biopsy and 
analysed by either polymerase chain reaction (PCR), fluorescence in situ hybridization 
(FISH) or array-comparative genomic hybridization (array-CGH) in order to determine 
a specific genetic defect or a chromosomal abnormality.2 
 
It is hypothesized that assisted reproductive technologies, especially ore invasive 
techniques like ICSI, increase the risk on birth defects.3,4 The need for embryo biopsy 
makes PGD an even more invasive procedure than IVF(-ICSI) treatment alone. 
Consequently, the safety of PGD is an issue that needs constant scrutinizing, the more 
since the number of pregnancies after PGD is increasing over the years.5 Since the first 
PGD treatment was performed in the early 1990s, clinical studies on PGD pregnancies 
and children born after PGD did not report a higher rate of major congenital 
malformations when compared to IVF-ICSI children.6,7-12 The results of these studies 
raise concerns about adverse perinatal and neonatal outcome, like prematurity rate, 
the incidence of low and very low birth weight as well as the incidence of perinatal 
mortality. However, the reported data are derived fro  only one large and three 
small cohorts which makes collection of more data desirable. Also, these cohorts 
mostly contain data on pregnancies and children born after preimplantation genetic 
screening (PGS), and thus include couples with a history of infertility. 
 
This study presents mostly prospectively collected data concerning the perinatal 
outcome of all PGD pregnancies in the Netherlands between 1995 and 2014. PGS 
pregnancies are not included. In view of earlier reported concerns and accompanying 
importance for patients and health care providers the aim of this study is to establish 
the safety of PGD in the Netherlands and to contribute to the justification of PGD as a 
tool in heritable disease prevention. We focus on the congenital malformation rate 
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cohorts,  mainly  from  Belgium,  and  to  published  data  on  naturally  conceived 
pregnancies and children and IVF‐ICSI pregnancies and children. A future study on the 
Dutch  PGD  population with  comparison  to  Dutch  IVF‐ICSI  and  naturally  conceived 
children  is  desirable.  Thereby,  the  children  of  the Dutch  PGD  population were  not 
examined  by  the  research  group which  could  introduce  an  underestimation  of  the 
number of, mainly minor,  congenital malformations. As Robins  et  al.  reported  that 




Overall,  the  risk  on  major  malformations  in  PGD  children  seems  comparable  to 




attribute  to  an  increased  risk on  an  adverse perinatal outcome when  compared  to 
naturally conceived children. 




Preimplantation genetic diagnosis (PGD) offers couples at high risk for transmitting a 
genetic disease to their offspring an alternative to prenatal diagnosis or may enhance 
their probability of an ongoing pregnancy if one of the parents is carrier of a structural 
chromosomal abnormality.1 Couples opting for PGD have to go through IVF treatment 
with or without ICSI to obtain embryos for genetic analysis. Blastomeres or 
trophectoderm (TE) cells for diagnosis are procured through embryo bi psy and 
analysed by either polymerase chain reaction (PCR), fluorescence in situ hybridization 
(FISH) or array-comparative genomic hybridization (array-CGH) in order to determine 
a specific genetic defect or a chromosomal abnormality.2 
 
It is hypothesized that assisted reproductive technologies, especially more invasive 
techniques like ICSI, increase the risk on birth defects.3,4 The need for embryo biopsy 
makes PGD an even more invasive procedure than IVF(-ICSI) treatment alone. 
Consequently, the safety of PGD is an issue that needs constant scrutinizing, the more 
since the number of pregnancies after PGD is increasing over the years.5 Since the first 
PGD treatment was performed in the early 1990s, clinical studies on PGD pregnancies 
and children born after PGD did not report a higher rate of major congenital 
malformations when compared to IVF-ICSI children.6,7-12 The r sults of these studies 
raise concerns about adverse perinatal and neonatal outcome, like prematurity rate, 
the incidence of low and very low birth wei ht as well as the incidence of perinatal 
mortality. However, the reported data are derived from only one large and three 
small cohorts which makes collection of more data d sirable. Also, these cohorts 
mostly contain data on pregnancies and children born after preimplantation genetic 
screening (PGS), and thus include couples with a history of infertility. 
 
This study presents mostly prospectively collected data concerning the perinat l 
outcome of all PGD pregnancies in the Netherlands between 1995 and 2014. PGS 
pregna ci s are ot incl ded. In view of earlier reported concerns and ac ompanying 
importance for patients and health care providers the aim of this study is to establish 
the safety of PGD in the Nethe lands and to cont ibut  to the justification of PGD as a 
tool in heritable disease prevention. We focus on the congenital malformation rate 
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offered  to  couples  at  high  risk  for  conceiving  a  child with  a monogenic disorder,  a 
mitochondrial disorder or a  chromosomal anomaly.1‐3 Selecting unaffected embryos 
requires  an  in‐vitro  fertilization  (IVF)  treatment  with  or  without  intracytoplasmic 
sperm injection (ICSI) followed by genetic testing of one or more biopsied embryonic 
cells.  This  biopsy makes  PGD  a more  invasive  treatment  than most  other  forms  of 
ART.1‐3 
 






and  found  no  increased  risk  for  congenital  abnormalities  or  adverse  perinatal 
outcome.6 However, the health of older children born after PGD has not been studied 





mean  age  of  18.4  months.10  Some  studies  on  the  neurological  development  of 
children born after PGD  and PGS  report  an  increased use of medical diagnostics  in 






study  the possible effects of  the  IVF/ICSI  treatment,  since  ICSI  is  commonly used  in 
PGD to eliminate the contamination risk  from extraneous sperm DNA.1,2 The second 









Observational  cohort  study  and  comparison  of  5‐year‐old  children  born  after PGD  to  similar 
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The  children  were  assessed  between  January  2014  and  July  2018  at  either  the 
Department  of  Clinical  Genetics  at  MUMC+  or  the  Department  of  Reproductive 
Medicine at UMCU.  
 
The  first part of  the assessment  consisted of a  semi‐structured  interview about  the 
child’s health, development and birth parameters, and the health and medical history 
of the parents and any other children. Subsequently, the parents were asked to fill in 
a  comprehensive  questionnaire  about  the  child’s  medical  history  and  their  own 
mental  health  and  education  level.  Information  about  the  PGD  indication,  family 
history and parental carrier status was collected from medical files.  
 
Auxological  and  physical  data  about  the  children  were  collected  according  to  a 
standardized  protocol.  A  limited  number  of  trained  clinicians  performed  the 
examinations.  The  children’s  growth  and  nutritional  status  were  assessed  by 





The  physical  examination  concluded  with  a  dysmorphological  and  neurological 
examination that focused on the presence of major or minor congenital abnormalities 
(or  a  combination  thereof).  A  major  congenital  abnormality  was  defined  as  a 
structural,  functional  or  genetic  anomaly  diagnosed  at  birth  or  in  the  neonatal 
period.20  Minor  congenital  abnormalities  were  defined  as  disturbances  of 
phenogenesis with a prevalence  ≤4% or abnormalities as classified by Merks et al.21 









families,  since  this  may  affect  the  children’s  development  and  behavior.15  We 
hypothesize  that  the growth, health and motor development of  children born after 
PGD is comparable to that of children born after IVF/ICSI and children born after NC. 
We  aim  to give more  insight  into  the possible effects or  risks of PGD on  children’s 





All Dutch  children born  after PGD between 2007  and 2013  and  their parents were 
invited  to  participate  once  the  children  reached  the  age  of  five  years.  IVF/ICSI 





PGD  group  and were  also  invited when  they  reached  the  age of  five. The    IVF/ICSI 
treatment was performed at MUMC+. 
 
The  NC  group  consisted  of  children  born  to  parents  who  had  visited  the  clinical 
genetics department. They were either  recruited  from  couples who had  considered 
PGD,  but  eventually  declined,  or  from  couples  who  underwent  invasive  prenatal 
testing  (chorionic  villus  sampling  or  amniocentesis)  because  of  a  high  risk  of 




Children  were  excluded  from  participation  if  they  were  affected  with  either  the 
familial or an unrelated genetic disorder or if their or their parents’ understanding of 
the Dutch language was insufficient. 




Preimplantation genetic diagnosis (PGD) is an assisted reproductive technology (ART) 
that is used to select embryos without a specific familial genetic disorder.1 PGD can be 
offered to couples at high risk for conceiving a child with a monogenic disorder, a 
mitochondrial disorder or a chromosomal anomaly.1-3 Selecting unaffected embryos 
requires an in-vitro fertilization (IVF) treatment with or without intracytoplasmic 
sperm injection (ICSI) followed by genetic testing of one or more biopsied embryonic 
cells. This biopsy makes PGD a more invasive treatment than most other forms of 
ART.1-3 
 
The health of children born after ART is a frequently discussed topic.4 IVF and ICSI 
coincide with important processes during early embryo development, like epigenetic 
reprogramming and epigenetic stability.5 Embryo biopsy may have an additional effect 
on these processes. Therefore, it is advisable to evaluate the potential impact of PGD 
on the congenital abnormality rate, growth, general health and motor development of 
children born after PGD. We studied the perinatal health of children born after PGD 
and found no increased risk for congenital abnormalities or adverse perinatal 
outcome.6 However, the health of older children born after PGD has not been studied 
as intensively yet. Desmyttere et al. studied health and auxological data (outcome 
measures: weight, height, head, arm and waist circumference) of 2-year-old children 
born after PGD or preimplantation genetic screening (PGS).7,8 Some of these children 
were also studied at the age of 6 and compared to children born after ICSI.9 Banerjee 
et al. reported on the health, height and weight of ten children born after PGD with a 
mean age of 18.4 months.10 Some studies on the neurological development of 
children born after PGD and PGS report an increased use of medical diagnostics in 
these children and question their psychomotor development when compared to 
children born after natural conception (NC).8,11-14  
 
In the underlying study, we compare 5-year-old children born after PGD to similarly 
aged children born after IVF/ICSI (control group 1) and children from families with a 
genetic disorder born after NC (control group 2). The first control group was chosen to 
study the possible effects of the IVF/ICSI treatment, since ICSI is commonly used in 
PGD to eliminate the contamination risk from extraneous sperm DNA.1,2 The second 




invited  268  children  born  after  IVF/ICSI  to  participate  in  this  study,  of  whom 
90 children  (33.6%)  participated.  Four  of  those  90  children  were  twins.  Of  the 
217 children that we invited for the NC group, 58 children (26.7%) participated in the 
study; none of them were twins. One child was not  invited to participate  in the PGD 
group because of partial biotinidase deficiency  (not  related  to  the PGD  indication). 
Ten  children  were  not  invited  to  participate  in  the  NC  group  because  they  were 
affected  with  the  familial  genetic  disorder  (cystic  fibrosis,  nail‐patella  syndrome, 
congenital  disorder  of  glycosylation  type  1c,  Marfan  syndrome,  Waardenburg 




Table  4.1  summarizes  the  baseline  characteristics  of  the  participating  children  and 
their  parents.  The  three  groups  of  children  were  comparable  with  respect  to 
male/female ratio, child’s mean age at assessment, gestational age, birth weight and 
birth  order.  The  parental  education  level, maternal  BMI  and  alcohol  consumption 
during pregnancy were also comparable.  
 
There was  a  significant  age difference  between  the mothers  (P=0.015)  and  fathers 
(P=0.019) in the three groups. On average, PGD parents were the youngest. There was 
also  significant difference  in  the number of mothers who  smoked during pregnancy 
(P=0.002;  more  mothers  in  the  IVF/ICSI  group  smoked),  and  the  father’s  BMI 
(P<0.0001;  those  in  the  PGD  group  had  the  highest  BMI).  Two  fathers  in  the  PGD 
group had morbid obesity (BMIs of 40.91 and 42.90, respectively).  
 
Significantly more  children  in  the PGD group  than  in  the NC group  (P=0.001) had a 
living  affected  first‐degree  family member  (parent  or  sibling)  or  first‐degree  family 










Finally, all  the children underwent neuropsychological  tests:  the Wechsler Preschool 
and  Primary  Scale  of  Intelligence‐III‐NL  (WPPSI‐III‐NL)  and  the  Automated Working 
Memory  Assessment  battery  (AWMA).22‐24  These  neuropsychological  data  were 
reported elsewhere.25 
Statistics 
Data  analyses were  performed with  the  IBM  Statistical  Package  for  Social  Sciences 







test  or  a  Fisher’s  exact  test.  For  the major  abnormalities  and minor  abnormalities 
outcomes, we  performed  a multiple  logistic  regression  analysis  of  the  groups  and 








103  children  (55.7%)  participated.  Eighteen  of  those  103  children were  twins. We 




Preimplantation genetic diagnosis (PGD) is an assisted reproductive technology (ART) 
that is used to select embryos without a specific familial genetic disorder.1 PGD can be 
offered to couples at high risk for conceiving a child with a monogenic disorder, a 
mitochondrial disorder or a chromosomal anomaly.1-3 Selecting unaffected embryos 
requires an in-vitro fertilization (IVF) treatment with or without intracytoplas ic 
sperm injection (ICSI) followed by genetic testing of one or more biopsied embryonic 
cells. This biopsy makes PGD a more invasive treatment than most other for s of 
ART.1-3 
 
The health of children born after ART is a frequently discussed topic.4 IVF and ICSI 
coincide with i portant processes during early embryo development, like epigenetic 
reprogramming and epigenetic stability.5 Embryo biopsy may have an additional effect 
on these processes. Therefore, it is advisable to evaluate the potential impact of PGD 
on the congenital abnormality rate, growth, general health and motor develop ent of 
children born after PGD. We studied the perinatal health of children born after PGD 
and found no increased risk for congenital abnormalities or adverse perinatal 
outcome.6 However, the health of older children born after PGD has not been studied 
as intensively yet. Desmyttere et al. studied health and auxological data (outcome 
measures: weight, height, head, arm and waist circumference) of 2-year-old children 
born after PGD or preimplantation genetic screening (PGS).7,8 Some of these children 
were also studied at the age of 6 and compared to children born after ICSI.9 Banerjee 
et al. reported on the health, height and weight of ten children born after PGD with a 
mean age of 18.4 months.10 Some studies on the neurological development of 
children born after PGD and PGS report an increased use of medical diagnostics in 
these children and question their psychomotor development when compared to 
children born after natural conception (NC).8,11-14  
 
In the underlying study, we compare 5-year-old children born after PGD to similarly 
aged children born after IVF/ICSI (control group 1) and children from families with a 
genetic disorder born after NC (control group 2). The first control group was chosen to 
study the possible effects of the IVF/ICSI treatment, since ICSI is commonly used in 
PGD to eliminate the contamination risk from extraneous sperm DNA.1,2 The second 















Length (cm)  114.96 ± 5.41  113.56 ± 4.38  114.33 ± 4.86  0.15 
Weight (kg)   20.1 ± 2.7 (n=102)  19.7 ± 2.7 (n=90)  19.9 ± 2.2 (n=58)  0.34 
BMI (kg/m2)  15.2 ± 1.2 (n=102)  15.2 ± 1.4 (n=90)  15.2 ± 1.1 (n=58)  0.79 
Head circumference (cm)  51.6 ± 1.4  51.2 ± 1.4  51.4 ± 1.6  0.13 
Arm circumference (cm)  17.8 ±1.3 (n=102)  17.7 ± 1.7 (n=89)  17.8 ± 1.1 (n=58)  0.49 





to  the  incidence  of major  congenital  abnormalities  in  the  IVF/ICSI  (4.4%)  and  NC 
(8.6%)  groups.  We  found  no  relationship  between  major  and  minor  congenital 
abnormalities.  The  results  of  logistic  regression  analysis  for  major  and  minor 
abnormalities  showed  no  significant  relationships  with  predictors.  The  difference 
between  the  three groups remained  insignificant. Mean blood pressure values were 
comparable  for  all  three  groups.  The  majority  of  the  children  (82.5‐90.0%)  had 
experienced an acute  illness during  their  life  for which  they were seen by a general 
practitioner or  in  the emergency department. Most of  the acute consultations were 
because of acute wounds or high  fever. Some children suffered  from chronic  illness 
(most  commonly  gastrointestinal  problems  and  allergies),  but  the  incidence  was 
comparable  in  all  three  groups.  The most  frequently  consulted medical  specialists 
were pediatricians and ear‐nose‐throat specialists. An equal number of children in all 
three  groups  had  hospital  admissions  in  their medical  history  with  a  comparable 
































Age at assessment (years)  5.44 ± 0.24  5.38 ± 0.22  5.47 ± 0.29  0.16 


























































Smoking during pregnancy   3/103 (2.9%)  10/90 (11.1%)  0/58 (0%)  0.002 
Alcohol during pregnancy  2/103 (1.9%)  2/90 (2.2%)  5/58 (8.6%)  0.100 








































Table  4.2  provides  data  about  the  children’s  growth.  We  found  no  significant 
difference  between  the  three  groups  for  any  of  the  outcome measurements.  The 
children in the PGD group tended to be somewhat taller, though not significantly so, 
than  the children  in  the  two control groups  (P=0.15), and  they also had  the highest 
mean weight and largest head circumference. More precisely, the differences in mean 
height and head circumference were  less  than 0.5 cm and 1.5 cm, respectively, and 
the  difference  in  mean  weight  was  less  than  0.5  kg.  The  mean  BMI  was  similar 
(15.2 kg/m2)  for  all  three  groups  and  considered  normal.    Also,  we  found  no 




Preimplantation genetic diagnosis (PGD) is an assisted reproductive technology (ART) 
that is used to select embryos without a specific familial genetic disorder.1 PGD can be 
offered to couples at high risk for conceiving a child with a monogenic disorder, a 
mitochondrial disorder or a chromosomal anomaly.1-3 Selecting unaffected embryos 
requires an in-vitro fertilization (IVF) treatment with or without intracytoplasmic 
sperm injection (ICSI) followed by genetic testing of one or more biopsied embryonic 
cells. This biopsy makes PGD a more invasive treatment than most other forms of 
ART.1-3 
 
The health of children born after ART is a frequently discussed topic.4 IVF and ICSI 
coincide with important processes during early embryo development, like epigenetic 
reprogramming and epigenetic stability.5 Embryo biopsy may have an additional effect 
on these processes. Therefore, it is advisable to evaluate the potential impact of PGD 
on the congenital abnormality rate, growth, general health and motor development of 
children born after PGD. We studied the perinatal health of children born after PGD 
and found no increased risk for congenital abnormalities or adverse perinatal 
outcome.6 However, the health of older children born after PGD has not been studied 
as intensively yet. Desmyttere et al. studied health and auxological data (outcome 
measures: weight, height, head, arm and waist circumference) of 2-year-old children 
born after PGD or preimplantation genetic screening (PGS).7,8 Some of these children 
were also studied at the age of 6 and compared to children born after ICSI.9 Banerjee 
et al. reported on the health, height and weight of ten children born after PGD with a 
mean age of 18.4 months.10 Some studies on the neurological development of 
children born after PGD and PGS report an increased use of medical diagnostics in 
these children and question their psychomotor development when compared to 
children born after natural conception (NC).8,11-14  
 
In the underlying study, we compare 5-year-old children born after PGD to similarly 
aged children born after IVF/ICSI (control group 1) and children from families with a 
genetic disorder born after NC (control group 2). The first control group was chosen to 
study the possible effects of the IVF/ICSI treatment, since ICSI is commonly used in 
PGD to eliminate the contamination risk from extraneous sperm DNA.1,2 The second 












Low birth weight  is common  in children born after  IVF/ICSI and  is often  followed by 
catch‐up growth during  late  infancy. Such catch‐up growth  is associated with  raised 
blood pressures and a higher risk  for disorders  like diabetes mellitus  type 2, obesity 
and  cardiovascular disease  later  in  life.26‐28 Also,  several  studies on mice born after 








caused by  the  treatment.  This  contradicts  the Developmental Origin of Health  and 
Disease  hypothesis,  which  states  that  exposure  to  a  stressful  environment  during 
early pregnancy,  and maybe  even during  the preimplantation period,  increases  the 
risk of a variety of diseases later in life.30,31 Desmyttere et al. may have seen an early 
effect of  the  embryo biopsy,  and  thus  a possible  stressful  environment, on health, 
since  they  reported  that children born after PGD/PGS  receive more complementary 
medical examinations than children born after  IVF/ICSI or NC.8 Studies on mice born 
after blastomere biopsy also  report an adverse  stress  response which can  influence 









of  the  children  had  normal  neurological  examinations  (i.e.,  they  performed  all  the 
exercises and tests as expected for their age). The other 10% of children scored below 





  PGD (n=103)  IVF/ICSI (n=90)  NC (n=58)  P‐value 
Major abnormality  6/103 (5.8%)ǂ  4/90 (4.4%)¥  5/58 (8.6%)µ  0.59 
3 or more minor abnormalities§  13/103 (12.6%)  15/90 (16.7%)  5/58 (8.6%)  0.35 
Systolic blood pressure (mmHg)  96.8 ± 11.8 (n=98)  96.2 ± 13.0 (n=83)  95.6 ± 10.2 (n=58)  0.60 
Diastolic blood pressure (mmHg)  59.2 ± 13.4 (n=98)  59.1 ± 16.5 (n=83)  55.6 ± 9.6 (n=58)  0.40 
Acute illness   86/100 (86.0%)  81/90 (90.0%)  47/57 (82.5%)  0.41 
Chronic illness  43/100 (43.0%)  34/90 (37.8%)  15/57 (26.3%)  0.11 
Medical specialist consultation  60/100 (60.0%)  48/90 (53.3%)  33/57 (57.9%)  0.65 
Hospital admission  19/99 (19.2%)  24/90 (26.7%)  16/57 (28.1%)  0.34 
Admission duration (days)  4.4 ± 7.0 (n=19)  7.2 ± 15.6 (n=24)  5.8 ± 5.1 (n=16)  0.13 
Paramedics consultation  45/100 (45.0%)  38/90 (42.2%)  23/57 (40.4%)  0.84 
ǂ  Inguinal  herniation  (n=2),  congenital  heart  defect  (n=2),  umbilical  herniation;  ¥  Hydroneprhosis,  cleft 




  PGD (n = 103)  IVF/ICSI (n = 90)  NC (n = 58)  P‐value 
Mean sitting age (months)  7.7 ± 2.0 (n=81)  7.1 ± 1.5 (n=69)  7.9 ± 2.0 (n=47)  0.04 
Mean walking age (months)  14.7 ± 3.3 (n=95)  13.8 ± 2.4 (n=84)  13.8 ± 2.2 (n=54)  0.11 
Mean age first word (months)  11.7 ± 3.9 (n=72)  11.0 ± 3.0 (n=64)  11.4 ± 4.4 (n=47)  0.70 







We  found  that  the  growth  parameters  in  5‐year‐old  children  born  after  PGD were 
comparable  to  those  of  similar  aged  children  born  after  IVF/ICSI  and  naturally 
conceived  children  from  families  with  a  genetic  disorder.  A  study  of  6‐year‐old 
children  born  after  PGD  showed  no  difference  in  BMI when  compared  to  children 




Preimplantation genetic diagnosis (PGD) is an assisted reproductive technology (ART) 
that is used to select embryos without a specific familial genetic disorder.1 PGD can be 
offered to couples at high risk for conceiving a child with a monogenic disorder, a 
mitochondrial disorder or a chromosomal anomaly.1-3 Selecting unaffected embryos 
requires an in-vitro fertilization (IVF) treatment with or without intracytoplasmic 
sperm injection (ICSI) followed by genetic testing of one or more biopsied embryonic 
cells. This biopsy makes PGD a more invasive treatment than most other forms of 
ART.1-3 
 
The health of children born after ART is a frequently discussed topic.4 IVF and ICSI 
coincide with important processes during early embryo development, like epigenetic 
reprogramming and epigenetic stability.5 Embryo biopsy may have an additional effect 
on these processes. Therefore, it is advisable to evaluate the potential impact of PGD 
on the congenital abnormality rate, growth, general health and motor development of 
children born after PGD. We studied the perinatal health of children born after PGD 
and found no increased risk for congenital abnormalities or adverse perinatal 
outcome.6 However, the health of older children born after PGD has not been studied 
as intensively yet. Desmyttere et al. studied health and auxological data (outcome 
measures: weight, height, head, arm and waist circumference) of 2-year-old children 
born after PGD or preimplantation genetic screening (PGS).7,8 Some of these children 
were also studied at the age of 6 and compared to children born after ICSI.9 Banerjee 
et al. reported on the health, height and weight of ten children born after PGD with a 
mean age of 18.4 months.10 Some studies on the neurological development of 
children born after PGD and PGS report an increased use of edical diagnostics in 
these children and question their psychomotor development when compared to 
children born after natural conception (NC).8,11-14  
 
In the underlying study, we compare 5-year-old children born after PGD to similarly 
aged children born after IVF/ICSI (control group 1) and children from families with a 
genetic disorder born after NC (control group 2). The first control group was chosen to 
study the possible effects of the IVF/ICSI treatment, since ICSI is commonly used in 
PGD to eliminate the contamination risk from extraneous sperm DNA.1,2 The second 




In  conclusion,  the  results  of  this  study  suggest  that  children  born  after  PGD  have 
normal  growth  and  motor  development  and  have  no  increased  risk  of  health 
problems in the first years of life. This study contributes to the knowledge about the 
growth,  health  and motor  development  of  children  born  after  PGD.  Still,  because 
adverse growth during childhood can increase the risk of cardiovascular disease later 




Our  results  about  the  motor  development  of  5‐year‐old  children  born  after  PGD 
support  previously  published  results  on  the  cognitive  and  socio‐emotional 
development of  children  born  after  PGD.14,25 However,  our  results  are  inconsistent 
with other published studies that found lower motor development scores for children 
born after PGS, and thus with embryo biopsy, than for children born after IVF.12,13 One 
difference  between  PGD  and  PGS  families  is  that  some  of  the  parents  in  the  PGD 
families are affected with a genetic disorder and thus have a somatic illness. Having a 
somatically  ill parent  can  cause  regression of  recently acquired  skills.15,25 Reasoning 
further, one would expect  to  find worse motor development  in  children born after 
PGD than  in children born after  IVF, rather than  lower motor development scores  in 
children born after PGS  than  in  children born after  IVF.    In  this  study,  some of  the 
children in the PGD and the NC groups had a somatically ill parent, but we could not 
confirm that the parental  illness affected the children’s motor development. It  is not 
known  why  PGS  children  have  less  favorable  results  for motor  development.  Our 




The strength of our study  is the  inclusion of a relatively  large group of children born 
solely after PGD, and not a  combination of PGD and PGS. Furthermore, we are  the 
first to assess the growth, health and motor development of such children at an older 
age  and  to  compare  them  to  children  born  after NC.  Choosing  a  control  group  of 
naturally conceived children from families with a genetic disorder is unique and gave 
us  the  opportunity  to  study  the  possible  influences  of  the  genetic  burden  on  the 
children’s development. Unfortunately, the response rates and the absolute numbers 
in  the  IVF/ICSI  and NC group were  lower  than  in  the PGD  group. The difference  in 
response rate might be due to the fact that the parents of the children born after PGD 
had  a higher affinity with  the  research question  than  the parents  in  the other  two 
groups. Given the unequal response rate, some results, particularly regarding motor 










Preimplantation genetic diagnosis (PGD) is an assisted reproductive technology (ART) 
that is used to select embryos without a specific familial genetic disorder.1 PGD can be 
offered to couples at high risk for conceiving a child with a monogenic disorder, a 
mitochondrial disorder or a chromosomal anomaly.1-3 Selecting unaffected embryos 
requires an in-vitro fertilization (IVF) treatment with or without intracytoplasmic 
sperm injection (ICSI) followed by genetic testing of one or more biopsied embryonic 
cells. This biopsy makes PGD a more invasive treatment than most other forms of 
ART.1-3 
 
The health of children born after ART is a frequently discussed topic.4 IVF and ICSI 
coincide with important processes during early embryo development, like epigenetic 
reprogramming and epigenetic stability.5 Embryo biopsy may have an additional effect 
on these processes. Therefore, it is advisable to evaluate the potential impact of PGD 
on the congenital abnormality rate, growth, general health and motor development of 
children born after PGD. We studied the perinatal health of children born after PGD 
and found no increased risk for congenital abnormalities or adverse perinatal 
outcome.6 However, the health of older children born after PGD has not been studied 
as intensively yet. Desmyttere et al. studied health and auxological data (outcome 
measures: weight, height, head, arm and waist circumference) of 2-year-old children 
born after PGD or preimplantation genetic screening (PGS).7,8 Some of these children 
were also studied at the age of 6 and compared to children born after ICSI.9 Banerjee 
et al. reported on the health, height and weight of ten children born after PGD with a 
mean age of 18.4 months.10 Some studies on the neurological development of 
children born after PGD and PGS report an increased use of medical diagnostics in 
these children and question their psychomotor development when compared to 
children born after natural conception (NC).8,11-14  
 
In the underlying study, we compare 5-year-old children born after PGD to similarly 
aged children born after IVF/ICSI (control group 1) and children from families with a 
genetic disorder born after NC (control group 2). The first control group was chosen to 
study the possible effects of the IVF/ICSI treatment, since ICSI is commonly used in 
PGD to eliminate the contamination risk from extraneous sperm DNA.1,2 The second 
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Preimplantation genetic diagnosis (PGD) is an assisted reproductive technology (ART) 
that is used to select embryos without a specific familial genetic disorder.1 PGD can be 
offered to couples at high risk for conceiving a child with a monogenic disorder, a 
mitochondrial disorder or a chromosomal anomaly.1-3 Selecting unaffected embryos 
requires an in-vitro fertilization (IVF) treatment with or without intracytoplasmic 
sperm injection (ICSI) followed by genetic testing of one or more biopsied embryonic 
cells. This biopsy makes PGD a more invasive treatment than most other forms of 
ART.1-3 
 
The health of children born after ART is a frequently discussed topic.4 IVF and ICSI 
coincide with important processes during early embryo development, like epigenetic 
reprogramming and epigenetic stability.5 Embryo biopsy may have an additional effect 
on these processes. Therefore, it is advisable to evaluate the potential impact of PGD 
on the congenital abnormality rate, growth, general health and motor development of 
children born after PGD. We studied the perinatal health of children born after PGD 
and found no increased risk for congenital abnormalities or adverse perinatal 
outcome.6 However, the health of older children born after PGD has not been studied 
as intensively yet. Desmyttere et al. studied health and auxological data (outcome 
measures: weight, height, head, arm and waist circumference) of 2-year-old children 
born after PGD or preimplantation genetic screening (PGS).7,8 Some of these children 
were also studied at the age of 6 and compared to children born after ICSI.9 Banerjee 
et al. reported on the health, height and weight of ten children born after PGD with a 
mean age of 18.4 months.10 Some studies on the neurological development of 
children born after PGD and PGS report an increased use of medical diagnostics in 
these children and question their psychomotor development when compared to 
children born after natural conception (NC).8,11-14  
 
In the underlying study, we compare 5-year-old children born after PGD to similarly 
aged children born after IVF/ICSI (control group 1) and children from families with a 
genetic disorder born after NC (control group 2). The first control group was chosen to 
study the possible effects of the IVF/ICSI treatment, since ICSI is commonly used in 
PGD to eliminate the contamination risk from extraneous sperm DNA.1,2 The second 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































technology  (ART)  treatment,  the  latter  generally  being  offered  as  an  infertility 
treatment.  People  opting  for  PGD  either  suffer  from  a  specific  genetic  disorder 
themselves  or  are  aware  of  a  familial  genetic  disorder.  It  is  conceivable  that  the 
presence of this type of disease  in these families  is associated with a higher  level of 
psychological  burden, which might  pose  a  higher  health  risk  for  the whole  family 




PGD  with  data  from  children  born  after  ART  without  PGD,  and  with  data  from 
naturally conceived children (NC) from families suffering from similar genetic diseases. 
The need  for a  cell biopsy and  the effect of  this biopsy on  the  (mental) health and 




perinatal  outcome,  such  as  prematurity  and  low/very  low  birth  weight.10‐15 
Prematurity and  lower birth weight are associated with  lower  cognitive  functioning 
and  an  increased  risk of  impaired behavioural development  at  follow‐up  in  school‐
aged  children,  however,  results  from  studies  investigating  cognitive  outcomes  in 
school‐aged children conceived after ART are mostly reassuring.16‐23 
To  date,  only  a  few  systematic  studies  have  assessed  the  cognitive  and  socio‐
emotional  development  of  children  born  after  PGD.  Internationally,  data  from  five 
PGD cohorts have been published.7,24‐30  
Although these studies provide reassuring results concerning the cognitive and socio‐
emotional  development  of  infants  and  (pre‐)school‐aged  children  born  after  PGD, 














 A  limited  number  of  studies with  small  sample  sizes  indicate  that  the  cognitive  and  socio‐
emotional development of (pre)school‐aged children born after either PGD or preimplantation 















The mean  full‐scale  IQ  scores  (p=0.426)  and performance on  the AWMA  Listening  Span  task 
(p=0.873) and Spatial Span task (p=0.458) were comparable between the three groups.  
Regarding  socio‐emotional  development,  the  teachers’  scores  revealed  more  externalising 
(p=0.011)  and  total  problem  (p=0.019)  behaviour  in  PGD  children  than  for  IVF/ICSI  children; 
both  groups  did  not  differ  significantly  from  the  NC  children  (p=0.11).  Though  considered 










PGD  children  show  normal  levels  of  cognitive  and  socio‐emotional  development  at  5  years, 
despite the biopsy involved in PGD and the potential extra psychological burden associated with 
the presence of a genetic disorder in the family.  
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PGD  children had  an  initial  consultation  at Maastricht University Medical Center+’s 
(MUMC+) clinical genetics department,  followed by  IVF/ICSI  treatment at either  the 
MUMC+  or  at  one  of  the  IVF  transport‐centers  at  the  University Medical  Center 
Utrecht (UMCU) or Groningen (UMCG). All biopsies were taken on day three, and all 
PGD  analyses were performed  at  the MUMC+. The parents of  the  IVF/ICSI  children 
underwent  treatment at  the MUMC+. The parents of  the NC children either had an 
informative  consultation  regarding  PGD  but  refrained  from  PGD  treatment  and 
became naturally pregnant, or had  invasive prenatal testing  (chorion villus biopsy or 






weight and  the medical history of  the parents,  the child and potential siblings were 
recorded.  Subsequently,  the parents were  asked  to  complete  the Behaviour Rating 
Inventory of Executive Functions (BRIEF) and Child Behaviour Checklist (CBCL), as well 
as  a  questionnaire  on  their  educational  level,  marital  status  and  additional 
information on the medical history of their child. Each child’s teacher was asked to fill 
in two questionnaires (BRIEF and Caregiver‐Teacher Report Form (C‐TRF)). 
The  children  underwent  an  auxological,  physical  and  neurological  examination,  of 




















after  PGS may  not  be  attributable  to  the  embryo  biopsy,  but  to  factors  related  to 
infertility or maternal age.33,34 Therefore, more research is needed that compares the 
cognitive and socio‐emotional development of children born after PGD. These should 
specifically  focus  on  older  children  and  later  cognitive  and  socio‐emotional 
development  and  should  include multiple  control  groups  accounting  for  potential 




We  compared  children  born  after  PGD with  two  control  groups:  IVF/ICSI  children  to 
measure the impact of the fertility/ART treatment in general, and with NC children from 
families with a genetic disorder to measure the effect of a familial genetic disorder and 
its  potential  emotional/psychological  impact  on  parents/children.  Whereas  many 
previous  studies  have  only  assessed  2‐3  year  old  children,  we  included  5‐year‐old 







group  from  families with a genetic disorder  (n=35). All children  (n=138) were Dutch 




Preimplantation genetic diagnosis (PGD) was first performed in 1990. It offers couples at 
risk of conceiving children with genetic disorders the opportunity to have an unaffected 
child of their own.1 In-vitro fertilisation (IVF)-treatment with or without intracytoplasmic 
sperm injection (ICSI) is required for PGD; this is followed by a biopsy of one or a few 
cells on day three, five or six after fertilisation. This biopsy is obligatory in order to select 
embryos that are not affected by the familial genetic disorder.2 
The indication for PGD is different from the indication for other assisted reproductive 
technology (ART) treatment, the latter generally being offered as an infertility 
treatment. People opting for PGD either suffer from a specific genetic disorder 
themselves or are aware of a familial genetic disorder. It is conceivable that the 
presence of this type of disease in these families is associated with a higher level of 
psychological burden, which might pose a higher health risk for the whole family 
system, including the development of problem behaviour in their children.3 The 
presence of chronic illness in siblings or parents has been shown to increase the risk of 
behavioural problems in otherwise healthy children.4-6 There is thus a need to collect 
and compare data on cognitive and behavioural development of children born after 
PGD with data from children born after ART without PGD, and with data from 
naturally conceived children (NC) from families suffering from similar genetic diseases. 
The need for a cell biopsy and the effect of this biopsy on the (mental) health and 
cognitive development of the children has also been a point of concern ever since 
PGD treatment was instigated.7-9 To date, studies focusing on children born after ART 
have mostly included children born after IVF and/or ICSI. In general, there is evidence 
that children born after ART, especially multiples, have an increased risk of adverse 
perinatal outcome, such as prematurity and low/very low birth weight.10-15 
Prematurity and lower birth weight are associated with lower cognitive functioning 
and an increased risk of impaired behavioural development at follow-up in school-
aged children, however, results from studies investigating cognitive outcomes in 
school-aged children conceived after ART are mostly reassuring.16-23 
To date, only a few systematic studies have assessed the cognitive and socio-
emotional development of children born after PGD. Internationally, data from five 
PGD cohorts have been published.7,24-30  
Although these studies provide reassuring results concerning the cognitive and socio-
emotional development of infants and (pre-)school-aged children born after PGD, 
there are large differences between the studies in age range (most included infants 









deviations  from normality.  Therefore,  for  these dependent measures, ANOVA  tests 
were also performed on  (log)transformed data, but since  the ANOVA results  for  the 
non‐transformed  and  transformed  data  did  not  differ,  we  report  on  the  non‐
transformed  data.  Outlier  analyses were  performed  by  inspection  of  boxplots  and 
reported  in  the results section. An outlier was defined as a score of either + 3SD or 





A  total of 72 PGD children, 128  IVF/ICSI children and 108 NC children, were  invited  to 
participate. Fifty‐one (including two twin pairs), 52 and 35 children respectively, and their 
parent(s) were included. Participation rates were 70.8%, 40.6% and 32.4%, respectively. 
Table  5.1  summarizes  the  relevant  child‐specific  and  parental  characteristics  at 
baseline.  A  significant  age  difference  at  assessment  time was  noted  for  the  three 
groups  (F(2,  135)=5.289,  p=0.006,  ηp
2=0.073),  but  as  only  5‐year‐old  children were 
invited  for  participation,  the  mean  age  differentiation  in  months  was  negligible. 
Furthermore, all dependent measures were  age‐  (and mostly  sex)  standardized  (T‐) 
scores.  Since  no  significant  group  differences  were  found  for  any  of  the  other 
variables there was no need to include them as covariates in the ANOVA analyses.  
Characteristics PGD and NC group 
Six of the  invited children  in the NC group had a  late‐onset familial genetic disorder, 
but had an unknown genetic status. Only one of  these children was  included  in  the 
study.  All  other  invited  NC  children  were  unaffected,  as  assessed  by  prenatal  or 


























Data  analyses  were  performed  using  the  IBM  Statistical  Package  for  the  Social 
Sciences  (SPSS) version 23.0  (SPSS  Inc, Chicago,  IL). An alpha  level of  .05  (two‐sided) 
was applied for all analyses.  
To  test  for  potential  between‐group  differences  in  cognitive  (IQ, working memory, 








Preimplantation genetic diagnosis (PGD) was first performed in 1990. It offers couples at 
risk of conceiving children with genetic disorders the opportunity to have an unaffected 
child of their own.1 In-vitro fertilisation (IVF)-treatment with or without intracytoplasmic 
sperm injection (ICSI) is required for PGD; this is followed by a biopsy of one or a few 
cells on day three, five or six after fertilisation. This biopsy is obligatory in order to select 
embryos that are not affected by the familial genetic disorder.2 
The indication for PGD is different from the indication for other assisted reproductive 
technology (ART) treatment, the latter generally being offered as an infertility 
treatment. People opting for PGD either suffer from a specific genetic disorder 
themselves or are aware of a familial genetic disorder. It is conceivable that the 
presence of this type of disease in these families is associated with a higher level of 
psychological burden, which might pose a higher health risk for the whole family 
system, including the development of problem behaviour in their children.3 The 
presence of chronic illness in siblings or parents has been shown to increase the risk of 
behavioural problems in otherwise healthy children.4-6 There is thus a need to collect 
and compare data on cognitive and behavioural development of children born after 
PGD with data from children born after ART without PGD, and with data from 
naturally conceived children (NC) from families suffering from similar genetic diseases. 
The need for a cell biopsy and the effect of this biopsy on the (mental) health and 
cognitive d velopment of he children has also been a point of concern ever since 
PGD treatment w s in tigated.7-9 To date, studies focusing on children born after ART 
h v  mostly included children born after IVF and/or ICSI. In general, there is evidenc  
that children born after ART, especially multiples, have an increased risk of advers  
perinatal outcome, such as prem turity and low/very low birth wei ht.10-15 
Prematurity and low r birth w ight are associated with lower cognitive functioning 
and an increased risk of impaired behavioural development at follow-up in school-
aged children, however, results from studies investigating cognitive outcomes in 
school-aged children conceived after ART are mostly reassuring.16-23 
To date, only a few systematic studies have assessed the cognitive and socio-
emotional development of children born after PGD. Internationally, data from five 
PGD cohorts have been published.7,24-30  
Although these studies provide reassuring results concerning the cognitive and socio-
emotional development of infants and (pre-)school-aged children born after PGD, 
there are large differences between the studies in age range (most included infants 





  Invited  Participated  Participation % of total per 
group 
  PGD  NC  PGD  NC  PGD  NC 





























Parent carrier of X‐linked disorder  9  23  6 (67%)  8 (35%)  14%  23% 
Invited child deceased   /  2  /  /  /  / 
Total  72  108  51 (71%)  35 (32%)  100% (n=51)  100% (n=35) 
Values  are  n  unless  otherwise  stated.  Values  in  between  brackets  are  percentage  of  responders  to  the 
invitation.  *  parent(s)  is/are  carrier  of  a  genetic  disorder;  i.e.  balanced  chromosomal  translocation  or 









statistically  significant  differences  in  FSIQ,  VIQ  and  PIQ  between  the  three  groups 
(Table 5.3). All three groups scored above the population mean. 
Removal  of  outliers  did  not  change  the  ANOVA  results  and  were  thus  retained, 







than  the population mean  (>  than 98th percentile) scores. Removal of  these outliers 
did  not  affect  ANOVA  results  and  were  retained.  The  one‐way  ANOVA  analyses 











































































































































































































































































































































































































































































































































































































Preimplantation genetic diagnosis (PGD) was first performed in 1990. It offers couples at 
risk of conceiving children with genetic disorders the opportunity to have an unaffected 
child of their own.1 In-vitro fertilisation (IVF)-treatment with or without intracytoplasmic 
sperm injection (ICSI) is required for PGD; this is followed by a biopsy of one or a few 
cells on day three, five or six after fertilisation. This biopsy is obligatory in order to select 
embryos that are not affected by the familial genetic disorder.2 
The indication for PGD is different from the indication for other assisted reproductive 
techn logy (ART) treatment, the latter gen rally bei g offered as an infertility 
treatment. People opting for PGD either suffer from a specific genetic disorder 
themselves or are aware of a familial genetic disorder. It is conceivable that the 
presence of this type of disease in these families is associated with a higher level of 
psychological burden, which might pose a higher health risk for the whole family 
system, including the development of problem behaviour in their children.3 The 
presence of chronic illness in siblings or parents has been shown to increase the risk of 
behavioural problems in otherwise healthy children.4-6 There is thus a need to collect 
and compare data on cognitive and behavioural development of children born after 
PGD with data from children born after ART without PGD, and with data from 
naturally conceived children (NC) from families suffering from similar genetic diseases. 
The need for a cell biopsy and the effect of this biopsy on the (mental) health and 
cognitive development of the children has also been a point of concern ever since 
PGD treatment was instigated.7-9 To date, studies focusing on children born after ART 
have mostly included children born after IVF and/or ICSI. In general, there is evidence 
that children born after ART, especially multiples, have an increased risk of adverse 
perinatal outcome, such as prematurity and low/very low birth weight.10-15 
Prematurity and lower birth weight are associated with lower cognitive functioning 
and an increased risk of impaired behavioural development at follow-up in school-
aged children, however, results from studies investigating cognitive outcomes in 
school-aged children conceived after ART are mostly reassuring.16-23 
To date, only a few systematic studies have assessed the cognitive and socio-
emotional development of children born after PGD. Internationally, data from five 
PGD cohorts have been published.7,24-30  
Although these studies provide reassuring results concerning the cognitive and socio-
emotional development of infants and (pre-)school-aged children born after PGD, 
there are large differences between the studies in age range (most included infants 





Two outliers were  found  in  the  IVF/ICSI group  in  the mothers’ BRIEF data and  four 
outliers  in  the NC  group  for  the  fathers’ BRIEF data. The one‐way ANOVA  analyses 




(p=0.035)  after  removal  of  the  two  outliers.  Bonferroni  corrected  post‐hoc  tests, 
however, only showed  trend‐significant differences between  the PGD and  the other 
groups  (p=0.08  for both contrasts), with higher scores  in  the PGD group  (Table 5.4). 
Moreover,  the mean BRIEF Total T‐scores  from mothers,  fathers and  teachers were 








one‐way  ANOVA  analyses  including  all  children  revealed  no  significant  group 
differences between PGD,  IVF/ICSI and NC groups  in  internalising, externalising and 
total problem behaviour, as reported by mothers and fathers (Table 5.4). Exclusion of 
outliers did not  influence  the  fathers’  results, and only  influenced  the  result  for  the 
Externalising  problem  scale  as  rated  by  mothers,  now  becoming  significant  (was 
borderline  significant):  F  (2,129)=3,70,  p<0.05,  ηp
2=0.054.  However,  Bonferroni 























































































































































































































































































































































































































































































































































































































Preimplantation genetic diagnosis (PGD) was first performed in 1990. It offers couples at 
risk of conceiving children with genetic disorders the opportunity to have an unaffected 
child of their own.1 In-vitro fertilisation (IVF)-treatment with or without intracytoplasmic 
sperm injection (ICSI) is required for PGD; this is followed by a biopsy of one or a few 
cells on day three, five or six after fertilisation. This biopsy is obligatory in order to select 
embryos that are not affected by the familial genetic disorder.2 
The indication for PGD is different fr m the indication f r other assisted repr ductive 
technology (ART) treatment, the l tter g nerally being offered as an infertility 
treatment. People opting fo  PGD either suffer from a specific genetic disorder 
themselves or ar  aware of a familial genetic disorder. It is conceivable that th  
presence of this ty e of disease in these families i  associated with a higher l vel of 
psy h logical burden, which might pose a higher health risk for the whole family 
system, including the development of problem behaviour in their children.3 The 
presence of chronic illness in siblings or parents has been shown to increase the risk of 
behavioural problems in otherwise healthy children.4-6 There is thus a need to collect 
and compare data on cognitive and behavioural development of children born after 
PGD with data from children born after ART without PGD, and with data from 
naturally conceived children (NC) from families suffering from similar genetic diseases. 
The need for a cell biopsy and the effect of this biopsy on the (mental) health and 
cognitive development of the children has also been a point of concern ever since 
PGD treatment was instigated.7-9 To date, studies focusing on children born after ART 
have mostly included children born after IVF and/or ICSI. In general, there is evidence 
that children born after ART, especially multiples, have an increased risk of adverse 
perinatal outcome, such as prematurity and low/very low birth weight.10-15 
Prematurity and lower birth weight are associated with lower cognitive functioning 
and an increased risk of impaired behavioural development at follow-up in school-
aged children, however, results from studies investigating cognitive outcomes in 
school-aged children conceived after ART are mostly reassuring.16-23 
To date, only a few systematic studies have assessed the cognitive and socio-
emotional development of children born fter PGD. Int rnationally, data from fiv  
PGD cohorts have be n published.7,24-30  
Although these studies provide reassuring results concerning the cognitive and socio-
emotional development of infants and (pre-)school-aged children born after PGD, 
there are large differences between the studies in age range (most included infants 




















old  children born after PGD  in  the Netherlands. Overall, our  findings are  reassuring 
and comparable to those reported for PGD cohorts from other countries.7,24‐30 
We found no evidence for an adverse effect of PGD on the cognitive development of 
the children. No significant differences  in verbal, performance or  full‐scale  IQ‐scores 
between the three groups were found and all three groups had mean IQ‐scores above 
the  population  average.  A  possible  explanation  for  the  latter  is  the  relatively  high 
educational  level of  the parents. Earlier  studies have  reported  that ART couples are 
often more  highly  educated  compared  to  the  general  population.44,45  Their  results 
were supported by Winter et al., who also found no differences in IQ‐scores between 
children born after PGD or  ICSI, and NC children.29 Compared  to previous work, our 
study  incorporated  two  extra  working  memory  tests,  however  we  found  no 
differences  in verbal and visuo‐spatial working memory capacity between  the  three 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Preimplantation genetic diagnosis (PGD) was first performed in 1990. It offers couples at 
risk of conceiving children with genetic disorders the opportunity to have an unaffected 
child of their own.1 In-vitro fertilisation (IVF)-treatment with or without intracytoplasmic 
sperm injection (ICSI) is required for PGD; this is followed by a biopsy of one or a few 
cells on day three, five or six after fertilisation. This biopsy is obligatory in order to select 
embryos that are not affected by the familial genetic disorder.2 
The indication f r PGD is different from the indication for other assisted reproductive 
technol gy (ART) treatment, the latter generally being offered s an infertility 
tr atment. People opting for PGD either suffer from a specific genetic disorder 
themselves or are aware of a fami ial genetic disorder  It is conceivable that the 
pres nce of this ty e of disease in these f milies is associated with a higher lev l  
psychological burden, which might pose  higher health risk or the whole family 
system, including the d velopment of problem behaviour in their children.3 The 
presence of chronic illness in siblings or parents has been shown to increase the risk of 
behavioural problems in otherwise healthy children.4-6 There is thus a need to collect 
and ompare data on cognitive and behavioural development of children born after 
PGD with data from children born after ART without PGD, and with data from 
na urally conceived children (NC) from families suff ring from similar genetic diseases. 
The need for a cell biopsy and t  effect of this biopsy on the (ment l) h lth a d 
cognitive development of the children has also been a point f concern ever since 
PGD treatment was instigated.7-9 To date, studies focusing on childr n born after ART 
have mostly included children born after IVF and/or ICSI. In general, there is evidence 
that children born after ART, especially multiples, have an increased risk of adverse 
perinatal outcome, such as prematurity and low/very low birth weight.10-15 
Prematurity and lower birth weight are associated with lower cognitive functioning 
and an increased risk of impaired behavioural development at follow-up in school-
aged children, however, results from studies investigating cognitive outcomes in 
school-aged children conceived after ART are mostly reassuring.16-23 
To date, only a few systematic studies have assessed the cognitive and socio-
emotional development of children born after PGD. Internationally, data from five 
PGD cohorts have been published.7,24-30  
Although these studies provide reassuring results concerning the cognitive and socio-
emotional development of infants and (pre-)school-aged children born after PGD, 
there are large differences between the studies in age range (most included infants 












child’s  cognitive development. Furthermore, adding a non‐subjective  rater  (teacher) 
provided us with multi‐informant data, giving even more  insights  in a  child’s  socio‐
emotional and behavioural development. 
The higher response rate of the PGD group and the higher presence of affected first 
degree  family  members  in  this  group  is  possible  a  limitation.  The  difference  in 
response rate can,  in our view, be best explained by the higher affinity of parents  in 
the PGD group  to  the  research question due  to  the  fact  that  they had a  child born 
after PGD. The slightly different genetic background of the PGD and NC children could 
have  influenced  the  socio‐emotional  development  scores,  resulting  in  higher 
Externalising  behaviour  scores  in  PGD  children  and  lower  Externalising  behaviour 
scores  in  NC  children.  Another  possible  limitation  regarding  the  evaluation  of 




old  children  born  after  PGD  showed  cognitive  and  socio‐emotional  development 











The  socio‐emotional  development  scores  did  show  some  differences  between  PGD 
children and  the control groups. Whereas  fathers’ CBCL scores did not  reveal group 
differences, the mothers’ CBCL scores showed trend‐significant (p<0.1) higher scores 
on externalising problem behaviour  in  the PGD group compared  to  the  IVF/ICSI and 
NC  group.  Furthermore,  the  PGD  children’s  teachers  reported  significantly  higher 
scores  on  Externalising  and  Total  problem  behaviour  scales  compared  to  those  of 
IVF/ICSI  children, but  reported  similar  scores  for  the NC  children.  It  is  important  to 
realize  that  analyses  were  performed  on  standardized  scores,  and mean  problem 
behaviour  scores  on  all  scales  fell  well  within  (even  below)  that  of  the  normal 
population range and were thus not  indicative of any problem behaviour  in all three 
groups.  
Normal  socio‐emotional  development,  though  without  group  differences,  has  also 
been reported by other researchers.25,27,30,31  It seems unlikely that the presence of a 
familial  genetic  disorder  in  PGD  families  could  account  for  teacher’s  higher 
Externalizing  behavior  scores,  since  no  difference  was  seen  in  teachers’  ratings 
between  the  NC  (also marked  by  the  presence  of  genetic  disorders)  and  IVF/ICSI 
groups.  It  is worth  noting  that  the  participation  rate was  higher  in  the  PGD  group 
compared  to  the  NC  group  and,  whereas  NC  and  PGD  groups  had  largely  similar 
genetic disease family backgrounds, the PGD group included 13% more children with a 
first degree family member (mostly parent) affected with a genetic disorder. Although 
we  consider  it  unlikely,  we  cannot  exclude  that  this  might  have  influenced  the 
somewhat  higher  rating  of  Externalising  behaviour  scores  on  the  CBCL  in  the  PGD 
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Prematurity and lower birth weight are associated with lower cognitive functioning 
and an increased risk of impaired behavioural development at follow-up in school-
aged children, however, results from studies investigating cognitive outcomes in 
school-aged children conceived after ART are mostly reassuring.16-23 
To date, only a few systematic studies have assessed the cognitive and socio-
emotional development of children born after PGD. Internationally, data from five 
PGD cohorts have been published.7,24-30  
Although these studies provide reassuring results concerning the cognitive and socio-
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child of their own.1 I -vitro f rtilisation (IVF)-treatment with or with ut intracytoplasmic 
sperm injection (ICSI) is required for PGD; this is followed by a biopsy of one or a few 
cells on day three, five or six after fertilisation. This biopsy is obligatory in order to select 
embryos that are not affected by the familial genetic disorder.2 
The indication for PGD is different from the indication for other assisted reproductive 
technology (ART) treatment, the latte  gene ally being offere  as an infertility 
treatment. People opting for PGD either suffer from a specific genetic disorder 
themselves r ar  aware of a familial genetic disorde . It is conceivable that th  
presence of this type of disease in these families is associated with a higher level of 
psychological burden, which might pose a higher health risk for t e whole famil  
system, including the development of problem behaviour in their children.3 The 
presence of chronic illness in siblings or parents has been shown to increase the risk of 
behavioural problems in otherwise healthy children.4-6 There is thus a need to collect 
and compare data on cognitive and behavioural development of children born after 
PGD with data from children born after ART without PGD, and ith d ta fro  
naturally conceived children (NC) from families suffering from similar genetic diseases. 
The need for a c ll biopsy nd the effe t of this biopsy on the (mental) health and 
cognitive development of the children has also been a point of concern ever since 
PGD treatment was nstigated.7-9 To d te, studi s focusing on children born after ART 
have mostly included children born after IVF and/or ICSI. In general, there is evidence 
that childre  born after ART, especially multiples, have an increased risk of adverse 
perinatal outcome, such as prematurity and low/very low birth weight.10-15 
Prematurity and lower birth weight are associated with lower cognitive functioning 
and an increased risk of impaired behavioural development at follow-up in school-
aged children, however, results from studies investigating cognitive outcomes in 
school-aged children conceiv d after ART are mostly reassuring.16-23 
To date, only a few systematic studies have assessed the cognitive and socio-
emoti nal dev lopment of children born after PGD. Internationally, data from five 
PGD cohorts have been published.7,24-30  
Although these studies provide reass ring results concerning the cognitive and socio-
emotional development of infants and (pre-)school-aged children born after PGD, 
there are large differences between the studies in age range (most included infants 
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most  couples with  a  high  risk  of  transmitting  a  genetic  disorder  to  their  offspring. 
Executing  IVF with embryonic  cell biopsy, which  is part of  the PGD  treatment, was 
considered experimental  in the early years of PGD.1,2 The number of applications for 
PGD  has  however  increased  enormously  over  the  last  three  decades,  ending  up  in 




In  most  countries,  pregnancies  resulting  from  assisted  reproductive  technologies 
(ART;  including PGD) are comprehensively monitored by means of extra ultrasounds 
or  invasive  prenatal  testing  because  of  a  possible  increased  risk  of  congenital 
abnormalities  and  adverse  perinatal  outcome.5  The  Dutch  guideline  for  prenatal 













Up until  this  thesis,  the results of 25 years of PGD  in  the Netherlands had not been 
extensively evaluated yet. This thesis  is therefore an evaluation of our performances 
and about safety of PGD. 
Not  only  the  knowledge  about  the  health  of  children  born  following  PGD  in  the 
Netherlands  is  scarce, also  international data are  limited. Following  the ESHRE PGD 
consortium  guidelines,  all  parents  of  children  born  after  PGD  in  the  Netherlands 
Chapter 1 
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PGD. Whereas  IVF/ICSI  is  not  an  alternative  since  subfertility  is  not  the  reason  to 
perform PGD. 
Increasing number of genetic indications and recent innovations 
This  thesis  includes  solely  pregnancies  and  children  born  following  PGD  after 
blastomere biopsy at day three with either FISH, array‐CGH or PCR. All  included PGD 
treatments were performed before 2014, since  the studied children had  to be aged 
five  years  old  in  order  to meet  the  inclusion  criteria  of  our  follow‐up  study.  PGD 
practice is, however, changing and innovating over the years with the introduction of, 
for instance, new biopsy techniques and new diagnostic approaches.  
The number of couples  that apply  for PGD  is  increasing over  the years. This may be 
partly  due  to  the  growing  knowledge  of  both  genetic  counsellors  and  candidate 
couples of PGD. The expanded use of  internet,  for  instance, makes  is easier  for  the 
counsellors  and  the  couples  to  search  for  information  about  PGD.  Thereby,  the 
internet facilitates the possibility to reach a broad audience for publicity about PGD. 
Information  about  PGD  is  not  only more  accessible,  the  number  and  diversity  of 
disorders  for which PGD has been done has also  increased.3 The diagnostic  field  in 
genetics has developed tremendously over the last years, resulting in the discovery of 
the genetic cause for an increasing number of severe genetic disorders. Especially the 
implementation  of  whole  exome  sequencing  (WES)  makes  it  possible  to  examine 
several  genes  at  once  and  increases  the  diagnostic  success  rate,  resulting  in  the 
discovery of rare genetic disorders and a growing number of patients with a genetic 
diagnosis.  The  recent  introduction  of  preconception  carrier  screening  (PCS)  will 
identify  couples  who  are  at  risk  for  transmitting  one  or  more  (severe)  genetic 
disorder(s) to their offspring already before an established pregnancy.18,19  
Until  recently, most  PGD  treatments  have  been  performed  by  use  of  blastomere 
biopsy at the cleavage stage in combination with either FISH, array‐CGH, or PCR. The 
use  of  such  diagnostic  approach  desires  a  detailed  and,  in  case  of  FISH  or  PCR,  a 
personalized protocol. The development of such a personalized protocol  is complex, 
time consuming, and requests the involvement of the couples family members.2,7,20‐22 
Recently,  a  new  biopsy  method,  called  trophectoderm  biopsy  (TE  biopsy),  was 
Chapter 6 
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receive  a  follow‐up  questionnaire  after  the  birth  of  their  child  including  questions 
about  the  obtained  prenatal  care  and  ultrasounds  results,  details  regarding  the 
delivery and birth parameters of the child(ren).7 All parents are asked for consent for 
the request of additional medical data. The collected data are published annually in a 
national  open  access  year  report  and  are  also  included  in  the  international  PGD 
follow‐up  database  of  the  ESHRE  (European  Society  for  Human  Reproduction  and 
Embryology) PGD consortium.3,8 Up until now, actual evaluation of the Dutch data was 
lacking which is part of this thesis (Chapter 2 and 3). 
In  order  to  interpret  the  Dutch  data,  we  have  reviewed  the  existing  literature 
regarding  the  follow‐up  of  PGD  pregnancies  and  children  and  tried  to  uncover  the 
knowledge  gaps,  striking  findings  and discrepancies. Most published  follow‐up data 
where gathered by a Belgian study group, who compared their PGD data to data from 
pregnancies  and  children  following  IVF/ICSI  treatment.9‐11  Other,  mostly  smaller, 
cohorts were published by study groups from the UK, the USA, Israel and Denmark.12‐
15 We  found  that both,  the number of  included pregnancies and children per study, 
and the total number of executed studies were  low. Thereby, most of the published 





have  no  increased  risk  of  transmitting  a  genetic  disorder  to  their  offspring.  The 
presence  of  a  genetic  disorder  in  a  family  and  increased  risk  of  transmitting  such 
disorder to the offspring may also cause psychological burden related to the existence 
of  an  affected  future parent or  an  affected earlier  child.17 Data  from PGD  and PGS 
cohorts should therefore ideally be analysed separately. PGS is, up until now, not part 
of the Dutch regular IVF (with or without PGD) practice. This gave us the opportunity 






the  transmission of a genetic disorder.  It  is  therefore  that we choose  to add a  third 
control group of naturally conceived children from families with a genetic disorder (NC 




Background and aim of this thesis 
Nowadays, preimplantation genetic diagnosis (PGD) is part of regular health care for 
most couples with a high risk of transmitting a genetic disorder to their offspring. 
Executing IVF with embryonic cell biopsy, which is part of the PGD treatment, was 
considered experimental in the early years of PGD.1,2 The number of applications for 
PGD has however increased enormously over the last three decades, ending up in 
about 500 referrals per year in the Netherlands in 2019.3 Following the incre sing 
number of referrals, also inc asingly more children have been born after PGD. In the 
N therlands, th  Maastricht University Medical Center+ is the only licensed center to 
perform PGD under the condition of periodic evaluation and transparency.4 
In most countries, preg a cies resulting from assisted reproductive technologies 
(ART; includi g PGD) are comprehensively monitored by means of extra ultrasounds 
or i vasiv  prenatal testing because of a possible incr ased risk of congenital 
abnormalities and adverse perinatal outcome.5 The Dutch guideline for prenatal 
diagno tics has been revise  in 2019. Since then no additional monitoring has been 
advised for pregnancies after ART.6 Prenatal screening f r congenital abnormalities as 
part of regular Dutc  antenatal care consists of NIPT for an uploidy s reening and an 
ultrasound examination at 18-20 weeks g stational age. Postnatal surveillance is part 
of a nati nal s reening program executed by youth health care physicians. 
Participation in these scre ning programs is owever voluntarily. It can be considered 
striking that children who a  born after PGD are monitored as every other hild and 
on voluntary basis, in pr gnancy a  well as after birth. Especially, when c nsideri g 
the differe ces with international guidelines for pre- and postnatal care for ART 
pregnancies.5,6 By performing PGD we interfere in the early developmental period of 
life due to t  n c ssity of an embry  biopsy and an IVF p ocedu  with or without 
cryopreservation. Is it possible that such a co plex pr c du e has no (adverse) ffect 
on the pregnancy and the rowth and development of the children born after PGD? 
p until this thesis, the results of 25 ye rs of PGD in the Netherlands had not b en 
extensively valuated yet. This thesis is herefore an valuation of our performances 
and about safety of PGD. 
Not only the knowledge about the health of children born following PGD in the 
Netherlands is sc rce, also international data are limited. Following the ESHRE PGD 







risk  for obstetric complications was comparable  to  the risk  in  the control group and 
the children born after PGD had no  increased risk for adverse perinatal outcome. At 
the age of five they had a normal physical health and cognitive and socio‐emotional 






place  at  a  later  stage  in  embryonic  development  (day  5/6  vs. day  3). An  extended 
culture  time,  as  required  for  TE  biopsy,  may  be  associated  with  higher  clinical 
pregnancy rates but also with an  increased risk of some adverse perinatal outcome, 
particularly  preterm  birth.31,32  Other  studies  report  that  TE  biopsy  may  probably 
increase  the  risk  of  preeclampsia  and  thus  the  risk  of  a more  complex  pregnancy 
course and adverse prenatal outcome.33 Reasoning further, TE biopsy might  increase 
the  risk  for  stillbirths  and perinatal mortality  as more pregnancies  are  complicated 
due  to  preeclampsia  and  adverse  perinatal  outcome.  Earlier  studies  on  PGD  also 
report  concerns  regarding  fetal  mortality  after  PGD,  whereas  we  report  a  lower 
incidence of stillbirths in our group of PGD singletons (chapter 3).11,34 Most of our data 
were distracted from pregnancies following fresh embryo transfer, whereas TE biopsy 
must  be  followed  by  cryopreservation  in  order  to  gather  enough  time  for  genetic 
testing. Cryopreservation would decline  the  risk  for  adverse perinatal outcome  like 
stillbirths and low birth weight, but could induce other adverse outcomes like large for 
gestational  age.  Studies  on  adverse obstetric outcome  after  cryopreservation  show 
conflicting  results,  reporting  both  an  increased  and  decreased  risk  for  obstetric 
complications.35,36 Techniques  for cryopreservation change over  time and  the use of 
cryopreservation  makes  it  possible  to  transfer  embryos  in  a  more  natural  cycle. 





or  six  after  fertilization.23,24  In  contrast  to  blastomere  biopsy,  TE  biopsy makes  it 
possible  to aspirate more cells  (five  to  ten cells) and  thus more DNA  is available  for 
the genetic analysis. Moreover,  the TE biopsy  is  taken  from  the  trophectoderm not 
touching the  inner cell mass (ICM) which becomes the embryo proper. The timing of 
TE  biopsy makes  cryopreservation  of  the  embryos  necessary  as modern  diagnostic 
procedures  cannot be performed  and  completed  in  two days,  the window of  fresh 




a  novel  way  of  determining  whether  an  embryo  is  euploid  or  aneuploid.  Small 
embryonic DNA  fragments are  sequenced and  compared  to a  reference genome as 
well as counted. This technique makes is possible to detect both whole chromosomal 
aberrations and segmental chromosomal imbalances. Chromosomal analysis by use of 
NGS has  lower costs, has enhanced precision and makes  it possible  to  test multiple 
embryos at once.25,26 
An  efficient  alternative  to  single‐cell  PCR  for  monogenic  disorders  is  the  whole 
genome  amplification  and  SNP  haplotyping  approach.  This  technique  makes  it 
possible  to  identify  high‐risk  haplotypes  based  on  the  detection  of multiple  single 
nucleotide  polymorphic  markers  linked  to  the  gene  of  interest.  The  designed 




analysis  for  familial  monogenic  disorders  as  well  as  chromosomal  anomalies  and 
makes  it possible  to use  a  ‘one‐fits‐all’ protocol  instead of  a personalized protocol, 
which  is  therefore  termed  OnePGT  (Preimplantation  Genetic  Testing).23,24  OnePGT 
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General discu sion 
Background and aim of this thesis 
Nowadays, pre mplantation genetic diagnosis (PGD) is part of regular health care for 
most couples with a high risk of tra smitting a genetic disord r to their offspring. 
Ex cuting IVF with embryo ic cell biopsy, which is part of h  PGD treatment, w s 
considered experimental i  the early years of PGD.1,2 The number of applications for 
PGD as however i creased normously over the last three d cades, nding up in 
about 500 ferrals per year in the Netherlands in 2019.3 Followi g th  increas ng 
number of referrals, also increasingly more children have been born after PGD. In the 
Netherlands, the Maastricht University Medical Center+ is the only licensed center to 
perform PGD und r the condition of periodic evaluation and transparency.4 
In most countries, pregnancies resulting from assisted reproductive technologies 
(ART; including PGD) are comprehensively monitored by means of extra ultrasounds 
or invasive prenatal testing because of a possible increased risk of congenital 
abnormalities and adverse perinatal outcome.5 The Dutch guideline for prenatal 
diagnostics has been revised in 2019. Since then no additional monitoring has been 
advised for pregnancies after ART.6 Prenatal screening for congenital abnormalities as 
part of regular Dutch antenatal care consists of NIPT for aneuploidy screening and an 
ultrasound examination at 18-20 weeks gestational age. Postnatal surveillance is part 
of a national screening program executed by youth health care physicians. 
Participation in these screening programs is however voluntarily. It can be considered 
striking that children who are born after PGD are monitored as every other child and 
on voluntary basis, in pregnancy as well as after birth. Especially, when considering 
the differences with international guidelines for pre- and postnatal care for ART 
pregnancies.5,6 By performing PGD we interfere in the early developmental period of 
life due to the necessity of an embryo biopsy and an IVF procedure with or without 
cryopreservation. Is it possible that such a complex procedure has no (adverse) effect 
on the pregnancy and the growth and development of the children born after PGD? 
Up until this thesis, the results of 25 years of PGD in the Netherlands had not been 
extensively evaluated yet. This thesis is therefore an evaluation of our performances 
and about safety of PGD. 
Not only the knowledge about the health of children born following PGD in the 
Netherlands is scarce, also international data are limited. Following the ESHRE PGD 




increased  risk  for miscarriages.44 New  techniques  like  TE biopsy may, on  the other 
hand,  decrease  the  risk  for misdiagnosis  since more  cells  are  available  for  genetic 
analysis.45  The  implementation  of  NGS  in  the  current  PGD  practice  is  another 
important innovation and a significant improvement of the PGD procedure. Recently, 
a multi‐center evaluation  study on  the concordance between previous PGD analysis 





embryos  for more  than  one  condition  in  vitro,  and  thus  perform  ‘prenatal  and/or 
newborn screening’ just after conception instead of during pregnancy and after birth. 





lowers  the  test‐specific  costs  of  PGD.  This  can  contribute  to  the  debate  about  the 
strict  indications for PGD.  If the test  is  less time consuming and cheaper than earlier 
tests, why not broaden our  indications and give more couples  the option  to opt  for 
PGD. Also, this latter point, is matter of debate. 
Another  upcoming  innovation,  is  non‐invasive  preimplantation  genetic  testing  (NI‐
PGT).  This  technique  will  make  it  possible  to  test  for  genetic  disorders  without 
performing an embryo biopsy. The required embryonic DNA will be gathered from the 
blastocoel  fluid or  from  spent  culture media  instead of  from  the  embryo  itself. Up 
until  now,  it  is  however  not  fully  confirmed  whether  the  DNA  fragments  in  the 
blastocoel  fluid or  spent  culture media are a  reliable  source of embryonic genomic 
information.46,47  The  concordance  between  these  DNA  fragments  and  the  DNA 
derived directly from the embryo should be confirmed before  implementation of NI‐








included  in this thesis.  Implementation of our results  in current PGD practice should 
thus be done with certain caution. 
Remarkably, we reported a higher  incidence of monozygotic twins  in our PGD group 
than  in  our  IVF  group  (chapter  2).  Monozygotic  twin  pregnancies  have  higher 
complexity and higher risk for adverse perinatal outcome.37 ART is known to increase 
the  risk  for  monozygotic  twinning,  but  the  embryo  biopsy  in  PGD  may  play  an 
additional  role  in  the development of  such  twin pregnancies due  to  zona pellucida 
manipulation which may  lead to disruption and splitting of the  ICM.76‐39 TE biopsy  is 
performed  at  a  later  embryonic  stage  and  therefore  might  increase  the  risk  for 





for misdiagnosis  is  desirable. We  reported  only  a  few misdiagnoses  during  almost 
twenty‐five years of PGD. The  first misdiagnosis concerned a complex PGD protocol 
using  the  FISH  technique  for  a  chromosomal  translocation  including  the  X 
chromosome  (chapter  3).41  The  corresponding  pregnancy  resulted  in  an  early 
miscarriage due to a chromosomal imbalance. In more recent years there was another 
misdiagnosis  for  a  chromosomal  anomaly,  using  the  FISH  technique.  The  third 
misdiagnosis  concerned  a  twin  pregnancy  after  the  transfer  of  a  single  embryo 
following  PCR  for  an  autosomal  recessive  disorder  in  a  consanguineous  couple.42 
Misdiagnosis  can  occur  due  to  a human  error,  an  intrinsic  (embryonic)  error  or  an 
extrinsic  (technical) error or can  result  from an  intervening spontaneous pregnancy. 
Examples  of  these  errors  are,  for  instance,  misidentification  or  mislabelling, 
embryonic  mosaicism,  parental  contamination  or  recombination.  High  quality 
standards  in  the PGD  laboratories may  lower  the  risk of misdiagnosis but single cell 
diagnosis  remains  technically  challenging.20,43  Because  of  the  risk  for misdiagnosis 
invasive prenatal diagnosis (chorionic villus sampling or amniocentesis) is offered in all 
pregnancies  following  PGD.  The  necessary  procedures,  are  however  invasive,  and 
therefore increase the risk for miscarriages. This may be one of the reasons why most 
couples  do  not  choose  to  confirm  the  PGD  diagnosis  with  invasive  prenatal 
procedures.34  The  future  implementation  of  non‐invasive  prenatal  testing  and 
diagnosis  (NIPT/NIPD),  which  is  performed  on  cell‐free  fetal  DNA  derived  from 
maternal blood, will give couples the opportunity to test for misdiagnosis without the 




Background and ai  of his thesis 
Nowadays, preimplantation genetic diagnosis (PGD) is part of regular health care for 
most couples with a high risk of transmitting a genetic disorder to their offspring. 
Executing IVF with embryonic cell biopsy, which is part of the PGD treatment, was 
considered experimental in the early years of PGD.1,2 The number of applications for 
PGD has however increased enormously over the last three decades, ending up in 
about 500 referrals per year in the Netherlands in 2019.3 Following the increasing 
number of referrals, also increasingly more children have been born after PGD. In the 
Netherlands, the Maastricht University Medical Center+ is the only licensed center to 
perform PGD under the condition of periodic evaluation and transparency.4 
In most countries, pregnancies resulting from assisted reproductive technologies 
(ART; including PGD) are comprehensively monitored by means of extra ultrasounds 
or invasive prenatal testing because of a possible increased risk of congenital 
abnormalities and adverse perinatal outcome.5 The Dutch guideline for prenatal 
diagnostics has been revised in 2019. Since then no additional monitoring has been 
advised for pregnancies after ART.6 Prenatal screening for congenital abnormalities as 
part of regular Dutch antenatal care consists of NIPT for aneuploidy screening and an 
ultrasound examination at 18-20 weeks gestational age. Postnatal surveillance is part 
of a national screening program executed by youth health care physicians. 
Participation in these screening programs is however voluntarily. It can be considered 
striking that children who are born after PGD are monitored as every other child and 
on voluntary basis, in pregnancy as well as after birth. Especially, when considering 
the differences with international guidelines for pre- and postnatal care for ART 
pregnancies.5,6 By performing PGD we interfere in the early developmental period of 
life due to the necessity of an embryo biopsy and an IVF procedure with or without 
cryopreservation. Is it possible that such a complex procedure has no (adverse) effect 
on the pregnancy and the growth and development of the children born after PGD? 
Up until this thesis, the results of 25 years of PGD in the Netherlands had not been 
extensively evaluated yet. This thesis is therefore an evaluation of our performances 
and about safety of PGD. 
Not only the knowledge about the health of children born following PGD in the 
Netherlands is scarce, also international data are limited. Following the ESHRE PGD 











needed.  The  main  difference  between  PGD  and  PGS  is  the  indication  for  the 
treatment. The goal  in PGD  is  to select embryos without a  familial genetic disorder; 
the goal in PGS is to increase the pregnancy chance in IVF/ICSI by excluding aneuploid 
embryos. Parental characteristics, such as parental disease in the PGD group or male 
infertility  or  increased maternal  age  in  the  PGS  group,  could  have  influenced  the 
results of studies on the safety of the procedure and stresses the value of evaluating 
both forms of ART (PGD and PGS) as two separate entities. 




one  of  the  largest  PGD  study  groups  reported  so  far  (chapter  4  and  5).  Still,  the 




children  from  families with  a  genetic  disorder  (NC  group),  in  addition  to  a  control 
group  of  children  born  after  IVF/ICSI  (chapter  4  and  5).  The  genetic  status  of  the 
families in the NC group is comparable to the genetic status of families opting for PGD. 
The NC  group mostly  contained  children  form parents who  intended  to  choose  for 
PGD but eventually, for different reasons, conceived naturally and probably opted for 
prenatal  testing. Thus  the  choice  for  two  control groups, one  consisting of  children 
born  after  IVF/ICSI  and  one  being  the NC  group, made  it  possible  to  evaluate  the 
effect of the IVF/ICSI treatment as well as the effect of the genetic burden on top of 
the effect of the biopsy. 











this  finding  in  a  larger  group  of  children  from  different  ages  and  to  compare  the 
findings to population data. 
We also report on the cognitive and socio‐emotional development of these children 
(chapter 5). We  found  that  levels of  cognitive and  socio‐emotional development at 
the age of five are within the normal range. Only the teachers’ scores revealed more 
externalizing  and  total problem behavior  in  PGD  children  than  in  IVF  children.  This 
difference was not found when both groups of children were compared to the group 
of  naturally  conceived  (NC)  children. We  could  not  exactly  explain  this  finding  but 
found  that  the  children  in  the  PGD  group more  often had  an  affected  first  degree 
family member  than  the children  in  the NC group. We hypothesized  that  this could 







for  cardiometabolic  differences  between  children  born  after  ART  compared  to 
naturally  conceived  children.49‐53  Similar  to  fetal  epigenetic  programming  of 
metabolism  and  the  consequences  for  adult  health,  early  embryonic  epigenetic 
mechanisms  are  thought  to  play  an  important  role  in  ART‐induced  cardiovascular 
dysfunction with premature vascular ageing as a result.54 One of the clinical signs of 
vascular  dysfunction  in  children  born  after  ART  is  an  increased  arterial  blood 
pressure.51 Other  important cardiovascular alterations  in children born after ART are 
insulin  resistance,  endothelial  dysfunction,  arterial  stiffness  and  thickening  of  the 
intima  media.53  The  general  concern  is  that  these  alterations  ultimately  lead  to 
cardiovascular morbidity and mortality in later life. Specifically it would be interesting 
to  study  the additional effect of  the embryo biopsy on epigenetic mechanisms and 




Backgrou d and aim of this th sis 
Nowadays, preimplantation genetic diagnosis (PGD) is part of regular health care for 
most couples with a high risk of transmitting a genetic disorder to their offspring. 
Ex cuting IVF with embryonic cell biopsy, whi h is part of t e PGD treatment, was 
considered experimental in th  early y ar  of PGD.1,2 The numb r of applications fo  
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or invasive prenatal testing because of  possible increased risk of congenital 
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ultrasound examination at 18-20 weeks gestational age. Postnatal surveillance is part 
of a national screening program executed by youth health care physicians. 
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striking that children who a e born after PGD are monitored as every other child and 
on voluntary basis, in pregnancy as well as after birth. Especially, when consid ring 
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Up until his thesis, the r sults of 25 years f PGD in the Netherlands had not be  
extensiv ly evaluated yet. This thesis is theref re an evaluati n of our p rformances 
and ab u  safety of PGD. 
Not only the knowledge about the health of children born following PGD in the 
Netherlands is scarce, also internati nal data a  limited. Following the ESHRE PGD 
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Overall,  we  feel  that  the  results  of  the  currently  completed  PGD  procedures  are 
reassuring.  However,  continuous  follow‐up  is  definitely  desirable  since  innovative 
techniques have been implemented the last couple of years and should be evaluated 
as well. The current innovations in the world of PGD will not be the last innovations. 




regard  to  the  health  and  development  of  children  born  after  PGD  up  to  now. 
However,  this  information  should  be provided with  some  restraint,  because  of  the 
lack of data on the effect of new techniques and the lack of information about older 
children born after PGD. Currently,  there  seems  to be no need  to advise additional 
antenatal or postnatal screening in PGD pregnancies and children. 
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G neral di cussion 
Background and aim of this thesis 
Nowadays, preimplantation genetic diagnosis (PGD) is part of regular health care for 
most couples with a high risk of transmitting a genetic disorder to their offspring. 
Executing IVF with embryonic cell biopsy, which is part of the PGD treatment, was 
considered experimental in the early years of PGD.1,2 The number of applications for 
PGD has however increased enormously over the last three decades, ending up in 
about 500 referrals per year in the Netherlands in 2019.3 Following the increasing 
number of referrals, also increasingly more children have been born after PGD. In the 
Netherlands, the Maastricht University Medical Center+ is the only licensed center to 
perform PGD under the condition of periodic evaluation and transparency.4 
In most countries, pregnancies resulting from assisted reproductive technologies 
(ART; including PGD) are comprehensively monitored by means of extra ultrasounds 
or invasive prenatal testing because of a possible increased risk of congenital 
abnormalities and adverse perinatal outcome.5 The Dutch guideline for prenatal 
diagnostics has been revised in 2019. Since then no additional monitoring has been 
advised for pregnancies after ART.6 Prenatal screening for congenital abnormalities as 
part of regular Dutch antenatal care consists of NIPT for aneuploidy screening and an 
ultrasound examination at 18-20 weeks gestational age. Postnatal surveillance is part 
of a national screening program executed by youth health care physicians. 
Participation in these screening programs is however voluntarily. It can be considered 
striking that children who are born after PGD are monitored as every other child and 
on voluntary basis, in pregnancy as well as after birth. Especially, when considering 
the differences with international guidelines for pre- and postnatal care for ART 
pregnancies.5,6 By performing PGD we interfere in the early developmental period of 
life due to the necessity of an embryo biopsy and an IVF procedure with or without 
cryopreservation. Is it possible that such a complex procedure has no (adverse) effect 
on the pregnancy and the growth and development of the children born after PGD? 
Up until this thesis, the results of 25 years of PGD in the Netherlands had not been 
extensively evaluated yet. This thesis is therefore an evaluation of our performances 
and about safety of PGD. 
Not only the knowledge about the health of children born following PGD in the 
Netherlands is scarce, also international data are limited. Following the ESHRE PGD 
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Background and aim of this thesis 
Nowadays, preimplantation genetic diagnosis (PGD) is part of regular health care for 
most couples with a high risk of tr nsmitting a genetic disorder to their offspring. 
Executing IVF with embryonic cell biopsy, which is part of the PGD treatment, was 
conside e  experimental in the early y ars of PGD.1,2 The number of applications for 
PGD has however increased enormously over the last three decades, ending up in 
about 500 referrals p r year in the Netherlands in 2019.3 Following the increasing 
number of referrals, also increasingly more children have been born after PGD. In the 
Nether ands, th  Maastricht University M dical Center+ is the only licen ed center t  
perform PGD under the condition of periodic evaluation and transparency.4 
In most countries, pregnancies resulting from assisted repr ductive technologies 
(ART; including PGD) are comprehensively monitored by means of extra ultrasounds 
or invasive p ena al t sting because of a possib e increased risk of congenital 
abnormalities and adverse perinatal outcome.5 The Dutch guideline for prenatal 
diagn stics has been r vised in 2019. Since then no additional monitoring has been 
advised for pregnancies after ART.6 Prenatal screening for congenital abnormalities as 
part of regular Dutch antenatal care consists of NIPT for aneuploidy screening and an 
ultrasound examination at 18-20 weeks gestational age. Postnatal surveillance is part 
of a national screening program executed by youth health care physicians. 
Participation in these screening programs is however voluntarily. It can be considered 
striking that children who are born after PGD are monitored as every other child and 
on voluntary basis, in pregnancy as well as after birth. Especially, when considering 
the differences with international guidelines for pre- and postnatal care for ART 
pregnancies.5,6 By performing PGD we interfere in the early developmental period of 
life due to the necessity of an embryo biopsy and an IVF procedure with or without 
cryopreservation. Is it possible that such a complex procedure has no (adverse) effect 
on the pregnancy and the growth and development of the children born after PGD? 
Up until this thesis, the results of 25 years of PGD in the Netherlands had not been 
extensively evaluated yet. This thesis is therefore an evaluation of our performances 
and about safety of PGD. 
Not only the knowledge about the health of children born following PGD in the 
Netherlands is scarce, also international data are limited. Following the ESHRE PGD 































Preimplantation  genetic  diagnosis  (PGD),  also  known  as  preimplantation  genetic 
testing  (PGT),  was  introduced  in  the  Netherlands  in  1995.  Currently,  around  500 
couples per year are referred for PGD. Couples opting for PGD have an increased risk 
of  transmitting  a  genetic  disorder  to  their  offspring  or  an  increased  risk  of 
miscarriages due to a structural chromosomal rearrangement. PGD makes  it possible 
to  select  embryos without  the  familial  genetic  disorder  or  the  familial  unbalanced 





The  complexity  of  the  procedure,  particularly  the  biopsy,  and  the  involvement  of 
human embryos makes PGD a morally  sensitive  technology.  It  is  therefore  that  the 
Maastricht University Medical Center+ (MUMC+) is the only Dutch center licensed to 
offer PGD  services. The MUMC+  collaborates with  three  so‐called  transport  centers 
(University Medical Center Utrecht, University Medical Center Groningen, Amsterdam 
University  Medical  Center).  Together  these  centers  form  the  alliance  PGD  the 
Netherlands. The activities of PGD the Netherlands are annually documented, but had 
not been evaluated up until this thesis. The Dutch data have also been incorporated in 







Chapter  2  describes  the  results  of  a  retrospective  study  on  the  risk  of  obstetric 
complications (including preeclampsia, HELLP, hypertension, gestational diabetes and 
placental problems) in pregnancies following PGD compared to pregnancies following 
IVF/ICSI.  All  included  pregnancies  were  conceived  between  2004  and  2014.  Data 
regarding parental characteristics (age, subfertility, genetic carrier status for the PGD 
couples),  the PGD and  IVF procedure  (use of  ICSI, number of biopsied cells, genetic 
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children  visited  the  hospital  to  undergo  the  examinations, with  a  total  turnaround 
time of about 3 hours. The growth (based on birth parameters, current height, weight 
and  body  circumferences)  was  comparable  for  all  three  groups.  Additionally,  the 
children underwent  a  general  and  a neurological  examination during which  tendon 
reflexes and coordination skills were evaluated. Most children performed  flawlessly, 
and a couple of children in all the three groups had some difficulty with standing and 




three  groups.  The mean  age  at which  early motor milestones were  achieved was 










the  cognitive and  socio‐emotional development  (chapter 5). All  children underwent 
extensive neuropsychological testing. Their parents and teachers were asked to fill in 
questionnaires  evaluating  the  children’s  executive  functioning  and  socio‐emotional 
development.  The  children  born  after  PGD  showed  levels  of  cognitive  and  socio‐
emotional development at the age of  five that are within the normal range. Striking 
was, though, that the teachers’ scores revealed more externalizing (e.g. hyperactive, 
aggressive)  and  total  problem  behavior  in  PGD  children  than  in  IVF  children.  This 
difference was not  found when both  groups of  children were  compared  to  the NC 
group.  This  finding  was  difficult  to  explain,  but  may  be  the  result  of  the  higher 
incidence of affected first degree family members  in the PGD group when compared 
to  the NC group. Since  the mean scores were within  the norm  range,  there was no 
prove that either the biopsy or the potential extra psychological burden resulting from 




measurements  were  presented  separately  for  singleton  and multiple  pregnancies. 
Additionally,  the  data  were  compared  to  national  population  data.  The  risk  of 
obstetric  complications  in  the  cohort  of  both  singleton  and  multiple  pregnancies 
following  PGD  was  comparable  to  the  risk  in  the  pregnancies  following  IVF/ICSI. 
Remarkable  findings  were  the  lower  incidence  of  stillbirths  in  the  PGD  singletons 
group and the higher  incidence of monozygotic twins  in the PGD multiple group. No 
explanation was found for the lower incidence of stillbirths. Future exploration of this 




pregnancies  following  PGD  that were  conceived  between  the  start  of  PGD  in  1995 
until  2014  were  included.  Data  were  collected  from  medical  files  and  by 
questionnaires filled  in by the parents. Most  important outcome measures were the 
incidence  of  congenital  abnormalities,  the  misdiagnosis  rate,  birth  parameters, 
perinatal mortality  and  hospital  admissions  in  the  perinatal  period.  The  data were 
compared to data from other published PGD cohorts and to population data.  The risk 
of  congenital  abnormalities was  not  increased  in  the  Dutch  PGD  cohort. Only  one 





the  population  norm.  Part  of  the  children  were  born  premature  and/or  small  for 
gestational age (SGA; 20% and 15% respectively). The incidence of hospital admissions 
in  this  cohort  was  comparable  to  the  incidence  of  prematurity  and  SGA,  which 





In  chapter  4  the  growth  and  health  of  five‐year‐old  children  born  after  PGD  was 
compared  to  that  of  children  born  after  IVF/ICSI  and  children  from  families with  a 
genetic disorder born after natural conception (NC). The execution of this study was 





Preimplantation genetic diagnosis (PGD), also known as preimplantation genetic 
testing (PGT), was introduced in the Netherlands in 1995. Currently, around 500 
couples per year are referred for PGD. Couples opting for PGD have an increased risk 
of transmitting a genetic disorder to their offspring or an increased risk of 
miscarriages due to a structural chromosomal rearrangement. PGD makes it possible 
to select embryos without the familial genetic disorder or the familial unbalanced 
karyotype. Briefly, the PGD treatment starts with an IVF (with or without ICSI) 
treatment in order to retrieve oocytes. The fertilization of the oocytes is followed by 
embryo biopsy and thereafter by genetic analysis of the biopsied cell(s). Only one, and 
sometimes two, unaffected embryos will be transferred into the uterus. 
 
The complexity of the procedure, particularly the biopsy, and the involvement of 
human embryos makes PGD a morally sensitive technology. It is therefore that the 
Maastricht University Medical Center+ (MUMC+) is the only Dutch center licensed to 
offer PGD services. The MUMC+ collaborates with three so-called transport centers 
(University Medical Center Utrecht, University Medical Center Groningen, Amsterdam 
University Medical Center). Together these centers form the alliance PGD the 
Netherlands. The activities of PGD the Netherlands are annually documented, but had 
not been evaluated up until this thesis. The Dutch data have also been incorporated in 
several reports of the European Society of Human Reproduction and Embryology 
(ESHRE). However, (international) data regarding the safety of PGD are scarce. 
 
The central aim of this thesis was to evaluate the safety of PGD, with special attention 
for the health of the women pregnant after PGD and for pre- and postnatal health of 
children conceived after PGD. 
 
Chapter 2 describes the results of a retrospective study on the risk of obstetric 
complications (including preeclampsia, HELLP, hypertension, gestational diabetes and 
placental problems) in pregnancies following PGD compared to pregnancies following 
IVF/ICSI. All included pregnancies were conceived between 2004 and 2014. Data 
regarding parental characteristics (age, subfertility, genetic carrier status for the PGD 
couples), the PGD and IVF procedure (use of ICSI, number of biopsied cells, genetic 


































Pre‐implantatie  genetische  diagnostiek  (PGD),  ook  wel  bekend  als  pre‐implantatie 
genetisch  testen  (PGT),  werd  in  1995  in  Nederland  geïntroduceerd.  Momenteel 
worden rond de 500 paren per jaar verwezen voor PGD. Paren die opteren voor PGD 
hebben een verhoogd risico op nakomelingen met een genetische aandoening of een 
verhoogd  risico  op  miskramen  ten  gevolge  van  een  structurele  chromosomale 
afwijking.  PGD maakt  het mogelijk  om  embryo's  te  selecteren  zonder  de  familiaire 
genetische  aandoening  of  de  familiaire  ongebalanceerde  chromosoomafwijking. 
Samengevat,  begint  de  PGD‐behandeling met  een  IVF‐behandeling  (met  of  zonder 









zogenaamde  transportcentra  (Universitair  Medisch  Centrum  Utrecht,  Universitair 
Medisch  Centrum  Groningen,  Amsterdam  Universitair  Medisch  Centrum).  Samen 
vormen deze 4 UMC’s “PGD Nederland”. De activiteiten van PGD Nederland worden 
jaarlijks gedocumenteerd, maar werden  tot nu  toe niet geëvalueerd. Daarnaast  zijn 
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PGD  vergeleken met die  van  kinderen  geboren na  IVF/ICSI  en  kinderen uit  families 
met een genetische aandoening geboren na natuurlijke conceptie (NC). De uitvoering 




en  lichaamsomtrek).  De  groei was  voor  alle  drie  groepen  vergelijkbaar.  Daarnaast 
ondergingen  de  kinderen  een  algemeen  lichamelijk onderzoek  en  een neurologisch 
onderzoek waarbij peesreflexen en coördinatievaardigheden werden geëvalueerd. De 
meeste kinderen presteerden feilloos, enkel een paar kinderen in alle drie de groepen 
hadden  enige  moeite  met  staan  en  springen  op  één  been.  Bij  geen  van  de 
geïncludeerde kinderen werden bij het neurologisch onderzoek afwijkingen gevonden. 
Tijdens het onderzoek van de kinderen werd aan de ouders gevraagd om vragenlijsten 
in  te  vullen  over  de  gezondheid, medische  voorgeschiedenis  en  vroege motorische 
ontwikkeling van hun kinderen. Evaluatie van de antwoorden van de ouders  toonde 
geen  verschil  tussen  de  drie  groepen.  De  gemiddelde  leeftijd  waarop  de  vroege 
motorische mijlpalen werden bereikt, was vergelijkbaar voor alle drie de groepen. Het 
percentage  kinderen met  een  acute  ziekte  in  hun medische  voorgeschiedenis was 
opvallend  hoog  in  alle  drie  de  groepen  (82,5‐90,0%).  Deze  bevinding  werd 
geïnterpreteerd  als  een  mogelijk  gevolg  van  voorzichtigheid  van  de  ouders  ten 
aanzien  van  de  gezondheid  van  hun  kinderen  die  op  een  niet‐natuurlijke  manier 
werden verwekt (PGD en  IVF/ICSI groep) of waarbij  in de zwangerschap aanvullende 








richt  zich  op  de  cognitieve  en  sociaal‐emotionele  ontwikkeling  (hoofdstuk  5).  Alle 
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werden  afzonderlijk  gepresenteerd  voor  eenling‐  en  meerlingzwangerschappen. 
Bovendien  werden  deze  gegevens  vergeleken  met  gegevens  van  de  Nederlandse 
bevolking. Het risico op obstetrische complicaties in het cohort van zowel eenling‐ als 
meerlingzwangerschappen  na  PGD  was  vergelijkbaar  met  het  risico  bij 
zwangerschappen na  IVF/ICSI. Opmerkelijke bevindingen waren de  lagere  incidentie 
van  intra‐uteriene vruchtdoden  in de PGD‐eenlinggroep en de hogere  incidentie van 
monozygote  (eeneiige)  tweelingen  in  de  PGD  groep.  Er  werd  geen  verklaring 
gevonden  voor  de  lagere  incidentie  van  intra‐uteriene  vruchtdoden.  Toekomstige 
evaluatie  van  deze  bevinding  werd  geadviseerd  omdat  eerdere  studies  wel  een 
mogelijk hogere foetale mortaliteit na PGD meldden. 
 
De  perinatale  gezondheid  van  de  kinderen  geboren  na  PGD wordt  geëvalueerd  in 
hoofdstuk  3. Alle  zwangerschappen die ontstonden na  PGD  tussen  1995  (start  van 
PGD)  en  2014  werden  geïncludeerd.  De  gegevens  werden  verkregen  middels 
dossieronderzoek  en  vragenlijsten  ingevuld  door  de  ouders  zelf.  De  belangrijkste 
uitkomstmaten  waren  de  incidentie  van  aangeboren  afwijkingen,  het  aantal 
misdiagnoses,  geboorteparameters,  perinatale  sterfte  en  ziekenhuisopnames  in  de 
perinatale  periode.  De  gegevens  werden  vergeleken  met  gegevens  van  andere 
gepubliceerde  PGD‐cohorten  en met  populatiegegevens.  Het  risico  op  aangeboren 
afwijkingen was  niet  verhoogd  in  het Nederlandse  PGD‐cohort.  Er was  slechts  één 
misdiagnose  gedurende  bijna  twintig  jaar  PGD.  Het  betrof  een  complex  PGD‐
onderzoek  voor  een  chromosomale  translocatie  waarin  het  X‐chromosoom  was 
betrokken.  De  bijbehorende  zwangerschap  resulteerde  in  een  vroege  miskraam 
vanwege  een  chromosomale  onbalans.  De  kinderen  in  dit  cohort  toonden  een 





drie  intra‐uteriene  vruchtdoden werden  gemeld,  twee  van  de  drie  kinderen waren 
deel van een meerlingzwangerschap. Geen van de kinderen overleed intra‐uterien ten 




Pre-implantatie genetische diagnostiek (PGD), ook wel bekend als pre-implantatie 
genetisch testen (PGT), werd in 1995 in Nederland geïntroduceerd. Momenteel 
worden rond de 500 paren per jaar verwezen voor PGD. Paren die opteren voor PGD 
hebben een verhoogd risico op nakomelingen met een genetische aandoening of een 
verhoogd risico op miskramen ten gevolge van een structurele chromosomale 
afwijking. PGD maakt het mogelijk om embryo's te selecteren zonder de familiaire 
genetische aandoening of de familiaire ongebalanceerde chromosoomafwijking. 
Samengevat, begint de PGD-behandeling met een IVF-behandeling (met of zonder 
ICSI) om eicellen te verkrijgen en vervolgens in het laboratorium te bevruchten. 
Enkele dagen na de bevruchting van deze eicellen vindt er een biopsie van het embryo 
plaats, gevolgd door genetische analyse van de gebiopteerde cel(len). Slechts één, en 
soms twee, niet-aangedane embryo's worden in de baarmoeder teruggeplaatst. 
 
De complexiteit van de procedure, met name de biopsie, en de betrokkenheid van 
menselijke embryo's maken PGD een moreel gevoelige technologie. Derhalve is het 
Maastricht Universitair Medisch Centrum (MUMC+) het enige Nederlandse centrum 
dat een vergunning heeft om PGD aan te bieden. Het MUMC+ werkt samen met drie 
zogenaamde transportcentra (Universitair Medisch Centrum Utrecht, Universitair 
Medisch Centrum Groningen, Amsterdam Universitair Medisch Centrum). Samen 
vormen deze 4 UMC’s “PGD Nederland”. De activiteiten van PGD Nederland worden 
jaarlijks gedocumenteerd, maar werden tot nu toe niet geëvalueerd. Daarnaast zijn 
deze data ook in meerdere rapportages van de “European Society of Human 
Reproduction and Embryology” (ESHRE) geïncludeerd. Echter, (internationale) studies 
over de veiligheid van PGD zijn schaars.  
 
Het hoofddoel van dit proefschrift was om de veiligheid van PGD te evalueren, met 
speciale aandacht voor de gezondheid van de vrouwen die zwanger zijn na PGD en 
voor de pre- en postnatale gezondheid van kinderen die verwekt zijn middels PGD. 
 
Hoofdstuk 2 beschrijft de resultaten van een retrospectief onderzoek naar het risico 
op obstetrische complicaties (inclusief preeclampsie, HELLP, hypertensie, zwanger-
schapsdiabetes en placentaire problematiek) in zwangerschappen na PGD vergeleken 


























kinderen  ondergingen  uitgebreide  neuropsychologische  testen  en  hun  ouders  en 







Deze  bevinding was moeilijk  te  verklaren, maar  kan  het  gevolg  zijn  van  de  hogere 
incidentie  van  een  aangedaan  eerstegraads  familieleden  in  de  PGD‐groep  in 
vergelijking met de NC‐groep. Omdat de gemiddelde  scores binnen het normbereik 




In hoofdstuk 6  recapituleren we de  resultaten  van de uitgevoerde onderzoeken en 
bespreken we de mogelijke effecten van nieuwe innovaties in de PGD‐praktijk op deze 








This  thesis  focuses  on  the  safety  of preimplantation  genetic  diagnosis  (PGD), more 




harm  to  a  patient  during  the  process  of  healthcare  and  reduction  of  risk  of 
unnecessary  harm  associated  with  healthcare  to  an  acceptable  minimum.  An 
acceptable  minimum  refers  to  the  collective  notions  of  given  current  knowledge, 





considered  to be an  invasive  treatment)  in  fertile women with or without a genetic 
disorder  themselves.  It  is  therefore,  that  both  government  and  society may  have 
concerns about the safety of this procedure. The Dutch government is involved in the 
legislation of PGD and decided  that only one Dutch center  is  licensed  to coordinate 
the activities  regarding PGD healthcare  in  the Netherlands, which  is  the Maastricht 
University Medical  Center+  (MUMC+).  Legal  and  ethical  boundaries  for  performing 
PGD are formulated in the ‘Embryowet’ and PGD guidelines were published in 2009 in 
the Staatscourant.2 Part of these guidelines is the obligation to provide annual reports 
on  the PGD cycles performed  in  the Netherlands. Drawing up  such annual  report  is 
also  advised  by  the    European  Society  of  Human  Reproduction  and  Embryology 
(ESHRE) PGD consortium.3 Up until this thesis, the Dutch data regarding pregnancies 
and children born following PGD had not been evaluated thoroughly and/or compared 
to  international data.  In  chapter 2 and 3 of  this  thesis we aimed  to evaluate  these 
data and gathered additional data in order to assess the short term safety of PGD with 
regard to the risk of adverse obstetric and perinatal outcome. Additionally, the  long 
term safety of PGD  is discussed  in chapter 4 and 5  in which the growth, health and 
development of 5‐year‐old children born after PGD is evaluated. Thereby, the majority 
of the couples whom may consider PGD has no fertility problem and could conceive 
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to  acknowledge when  evaluating  the  application of  PGD.  PGD makes  it possible  to 
select  embryos  without  a  certain  genetic  disorder  before  an  actual  pregnancy  is 
established.  Only  unaffected  embryos will  be  transferred  into  the  uterus.  Invasive 






suction  aspiration.  Such  procedures  can  have  large  psychological  impact  on  the 
couple,  especially  when  performed  in  several  consecutive  pregnancies.  The 
psychological  impact of  the PGD procedure, on  the other hand,  should  also not be 




The  preference  for  either  PGD  or  invasive  prenatal  testing  is  a  very  personal  one 
which may  change over  time or may be  influenced by  certain  (personal)  events or 
religious  background.  For  instance,  as  already  mentioned,  preconception  carrier 








for  healthcare  providers  and  other  professionals,  for  instance  teachers,  to  judge 







realistic  alternative  for  the  couples  opting  for  PGD. Data  on  the health  of  children 
born after PGD are  scarce and not easily accessible  for  couples who  consider PGD. 
Earlier studies on the health of newborns and children born following PGD are mostly 
published in scientific journals and written in scientific language which may be difficult 
to  read  for  non‐medics.  Thereby, most  of  these  studies  focus  on  preimplantation 
genetic  screening which  is offered  to couples with  subfertility  instead of  to  couples 
with a high chance of conceiving a child with a genetic disorder.  
 
In  the  last  couple  of  years,  the  number  of  referrals  for  PGD  has  increased 
tremendously.4 More couples apply for PGD. Also more hereditary disorders for which 
PGD can be offered can be diagnosed. The increasing number of diagnoses in patients 
in  whom  a  genetic  disorder  is  suspected  is  due  to  the  improvement  of  genetic 
diagnostic techniques. This consequently leads to the ascertainment of more couples 
with an  increased risk of conceiving a child with a genetic disorder. The  introduction 
and growing application of preconception carrier  tests  is another way of  identifying 
couples  at  risk  for  transmitting  a  genetic  disorder  to  their  offspring.  A  wider 
application of a delicate medical treatment such as PGD, that is administered with the 
involvement of the government, should be carefully evaluated. Not only the current 




As  with  each  medical  treatment  it  is  important  that  guidelines  are  followed. 
Additionally, the actual outcome should be in line with the expected outcome. In case 
of PGD,  the expected outcome  is  the birth of a healthy child, more  specifically of a 
child without the familial genetic disorder for which PGD was performed. The primary 
aim of PGD  is  to prevent  the birth of  a  child without  such  genetic disorder  and  to 
soften personal harm  for parents  and  families. As  a  side  effect PGD may  lead  to  a 
decline in healthcare costs since the diseases for which PGD is performed are, without 
exception,  severe  and  sometimes  even  lethal  at  a  young  age.  PGD,  on  itself,  is 
however  also  a  costly  medical  procedure.  It  is  therefore  important  to  evaluate 
whether  the  use  of  PGD  introduces  (new)  health  hazards  in  the  forthcoming 
pregnancy and offspring. The evaluation of such adverse effects  is also of economic 




This thesis focuses on the safety of preimplantation genetic diagnosis (PGD), more 
precisely on the growth, health and development of children born after PGD. The 
societal value of the results of this thesis is described in this paragraph. 
 
The World Health Organization defines ‘patient safety’ as “The absence of preventable 
harm to a patient during the process of healthcare and reduction of risk of 
unnecessary harm associated with healthcare to an acceptable minimum. An 
acceptable minimum refers to the collective notions of given current knowledge, 
resource available and the context in which care was delivered weighed against the 
risk of non-treatment or other treatment”.1 
 
PGD is a complex and morally sensitive technology that involves biopsy, analysis and 
selection of human embryos, as well as the application of in-vitro fertilization (which is 
considered to be an invasive treatment) in fertile women with or without a genetic 
disorder themselves. It is therefore, that both government and society may have 
concerns about the safety of this procedure. The Dutch government is involved in the 
legislation of PGD and decided that only one Dutch center is licensed to coordinate 
the activities regarding PGD healthcare in the Netherlands, which is the Maastricht 
University Medical Center+ (MUMC+). Legal and ethical boundaries for performing 
PGD are formulated in the ‘Embryowet’ and PGD guidelines were published in 2009 in 
the Staatscourant.2 Part of these guidelines is the obligation to provide annual reports 
on the PGD cycles performed in the Netherlands. Drawing up such annual report is 
also advised by the  European Society of Human Reproduction and Embryology 
(ESHRE) PGD consortium.3 Up until this thesis, the Dutch data regarding pregnancies 
and children born following PGD had not been evaluated thoroughly and/or compared 
to international data. In chapter 2 and 3 of this thesis we aimed to evaluate these 
data and gathered additional data in order to assess the short term safety of PGD with 
regard to the risk of adverse obstetric and perinatal outcome. Additionally, the long 
term safety of PGD is discussed in chapter 4 and 5 in which the growth, health and 
development of 5-year-old children born after PGD is evaluated. Thereby, the majority 
of the couples whom may consider PGD has no fertility problem and could conceive 
naturally. Especially for those, the knowledge about the safety of PGD for both 
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are  pregnant  following  Assisted  Reproductive  Technology  (ART),  in  particular 
following PGD. Whereas  the second part of  this  thesis  (chapter 4 and 5) may be of 







the  children’s  teachers  about  the  PGD  procedure.  Plain  and  easily  accessible 
information about PGD and  the  results of  this  thesis  is  thus desirable. We provided 
such  information  by  means  of  a  newsletter  to  all  parents  of  the  children  who 
participated in the study with five‐year‐old children. Additionally, results of the study 
have  been  published  in  summary  and  plain  language  on  the  website  of  PGD  the 
Netherlands. Stake holders and Dutch clinical geneticist whom counsel couples about 
PGD  have  been  informed  about  the  first  results  during  a  special  organized  stake 
holders day. 
 
This  thesis  is  the  start of a broader  follow‐up program  for  children born after PGD. 
This  program  includes  the  study  of  8‐year‐old  children  born  after  PGD, whom  are 
compared  to  IVF/ICSI  children  and  naturally  conceived  children  of  the  same  age. 
These 8‐year‐old children were the same children as  included  in the study of 5‐year‐
olds. Examining the children at an older age contributes to the knowledge about long‐
term  safety  of  PGD.  Additionally,  collection  of  complementary  data  on  body 
composition, blood pressure and vascular dysfunction is part of the program in order 
to collect information about cardiometabolic outcome in the three groups of children. 
This  information  is of  importance  for  the  future health of  the children since  it gives 
information about cardiovascular morbidity and mortality risks later in life. 
 
In  summary,  the evaluation of  the  safety of PGD  is not only an  important  scientific 
and/or medical  topic, but  is also socially and economically relevant. Techniques and 
procedures  necessary  for  PGD  are,  however,  quickly  developing  over  time,  due  to 
which  the  results of  this  thesis may become  less valuable  in  the nearby  future. The 
applied study methods and procedures can, though, be a blueprint for future follow‐
up studies on the safety of PGD. 




This thesis focuses on the safety of preimplantation genetic diagnosis (PGD), more 
precisely on the growth, health and development of children born after PGD. The 
societal value of the results of this thesis is described in this paragraph. 
 
The World Health Organization defines ‘patient safety’ as “The absence of preventable 
harm to a patient during the process of healthcare and reduction of risk of 
unnecessary harm associated with healthcare to an acceptable minimum. An 
acceptable minimum refers to the collective notions of given current knowledge, 
resource available and the context in which care was delivered weighed against the 
risk of non-treatment or other treatment”.1 
 
PGD is a complex and morally sensitive technology that involves biopsy, analysis and 
selection of human embryos, as well as the application of in-vitro fertilization (which is 
considered to be an invasive treatment) in fertile women with or without a genetic 
disorder themselves. It is therefore, that both government and society may have 
concerns about the safety of this procedure. The Dutch government is involved in the 
legislation of PGD and decided that only one Dutch center is licensed to coordinate 
the activities regarding PGD healthcare in the Netherlands, which is the Maastricht 
University Medical Center+ (MUMC+). Legal and ethical boundaries for performing 
PGD are formulated in the ‘Embryowet’ and PGD guidelines were published in 2009 in 
the Staatscourant.2 Part of these guidelines is the obligation to provide annual reports 
on the PGD cycles performed in the Netherlands. Drawing up such annual report is 
also advised by the  European Society of Human Reproduction and Embryology 
(ESHRE) PGD consortium.3 Up until this thesis, the Dutch data regarding pregnancies 
and children born following PGD had not been evaluated thoroughly and/or compared 
to international data. In chapter 2 and 3 of this thesis we aimed to evaluate these 
data and gathered additional data in order to assess the short term safety of PGD with 
regard to the risk of adverse obstetric and perinatal outcome. Additionally, the long 
term safety of PGD is discussed in chapter 4 and 5 in which the growth, health and 
development of 5-year-old children born after PGD is evaluated. Thereby, the majority 
of the couples whom may consider PGD has no fertility problem and could conceive 
naturally. Especially for those, the knowledge about the safety of PGD for both 

































Ten eerste was mijn proefschrift nooit  tot  stand  gekomen  zonder de deelnemende 
kinderen.  Ik  heb  genoten  van  de  inzet  en  trotse  gezichten  van  de  5‐  en  8‐jarige 
kinderen  tijdens  de  onderzoeksdagen  in  het  ziekenhuis  en  bij  de  kinderen  thuis. 
Sommige  kinderen  vonden het  spannend,  anderen  kletsten  aan  een  stuk door. We 
hebben heel veel mooie tekeningen mogen ontvangen. Ook de ouders en leraren van 
de deelnemende kinderen wil ik bedanken voor het (soms urenlang) invullen van onze 
vragenlijsten.  Net  als  de  kinderen  waren  de  deelnemende  ouders  ontzettend 
enthousiast en natuurlijk trots als een pauw wanneer hun kind, veelal met stralende 
glimlach, de onderzoekskamer uit kwam. Tevens hebben deze ouders mij onbewust 
gevormd  tot de klinisch geneticus die  ik nu ben, door hun verhaal met mij  te delen 
over de  impact  van de erfelijke aandoening op hun gezin en  in het dagelijks  leven. 






Natuurlijk  wil  ik  ook  graag  mijn  promotor  en  copromotoren  bedanken.  Prof.  dr. 
Christine  de Die‐Smulders,  beste  Christine,  ik  kan me  het moment  nog  herinneren 
waarop ik jou vertelde dat ik graag zou willen promoveren. Je was totaal niet verrast, 
maar  juist  in  afwachting  van  dit  besluit. Deze  reactie  tekent  jou,  je  hebt  oog  voor 
iemands professionele ontwikkeling maar ook voor de persoon achter de professional. 
Jij  begrijpt  dat  privé  en werk  soms  in  elkaar  overvloeien  en  gaf mij  de  ruimte  om 
daarmee om  te  leren gaan.  Je bent  kritisch en weet mij altijd  te  stimuleren om de 
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Gedurende  mijn  promotietraject  zijn  er  natuurlijk  nog  meer  collega’s  betrokken 
geweest die ik hier graag in willekeurige volgorde wil benoemen. Amber, tijdens mijn 








altijd  fijn  om  even  te  kunnen  sparren met mede‐promovendi.  Jullie  zijn  inmiddels 
gepromoveerd, nogmaals gefeliciteerd! Andrea, heel erg bedankt voor de statistische 
ondersteuning die  ik vaak zo hard nodig had, evenals  jouw  input als coauteur. Edith, 
Aimee en Jos bedankt voor jullie input in de stukken over de technische aspecten van 
PGD en  voor de gezellige  theekransjes  in de wandelgang.  Ik  vergeet nooit meer de 
‘bemoedigende’  vergelijking  van  Aimee  toen  ik  vertelde  dat  ik  zwanger  was: 
“promoveren en zwanger, dus jij gaat twee keer bevallen dit jaar?!”. Twee keer in één 
jaar  is door de huidige corona‐situatie niet gelukt, maar  ik ga des  te meer genieten 
van deze speciale ‘bevalling’! 
 
Zoals  eerder  genoemd  heb  ik  mijn  promotietraject  altijd  gecombineerd  met 
patiëntenzorg. Ik ben mijn collega’s van de klinische genetica dan ook dankbaar voor 




zeer welkome  afleiding  geweest.  Ik  hoop  dat  deze  dates  in  de  toekomst  nog  vaak 
mogen plaatsvinden, dus Suzanne laat het weten wanneer je weer in Nederland bent! 
Connie,  als  mijn  mentor  en  stagebegeleiding  heb  je  een  belangrijke  rol  in  mijn 
opleiding  gespeeld.  Je  bent  een  voorbeeld  voor  de  vrouwen  die  carrière  en 
moederschap willen combineren! Daarnaast wil ik je natuurlijk ook erg bedanken voor 
jouw  rol  als  voorzitter  van de beoordelingscommissie. Nienke  en Marieke, bedankt 
voor het wegwijs maken in alle PGD bestanden en follow‐up lijsten. Ook de dames van 








heden  zijn  wij  aan  elkaar  ‘gekoppeld’.  Je  begon  als  mijn  stagebegeleider,  werd 
vervolgens mijn opleider en al snel ook copromotor.  Ik waardeer  jouw  ‘to‐the‐point’ 
manier  van werken.  Jouw betrokkenheid  als  copromotor  én opleider  zal  soms best 
moeilijk zijn geweest maar deze combinatie heeft er mede voor gezorgd dat het mij 
gelukt  is  om  promotie  en  opleiding  te  combineren.  “Hoe  gaat  het  met  je?”  Een 
doodnormale  vraag die we  vaak  te pas  en  te onpas  stellen, maar  jij  lijkt hem heel 
doordacht en op de  juiste momenten  te  stellen. De gesprekken die hierop  volgden 
heb  ik  altijd  zeer  gewaardeerd  en hielpen mij om orde  in mijn hoofd  te  scheppen. 




Dr. Aafke  van Montfoort,  beste Aafke, wat was  je  verrast  toen  ik  vroeg  of  je mijn 
copromotor wilde worden. Voor mijzelf was hier geen twijfel over mogelijk. Ondanks 




heb  je mij  geholpen met de  statistische analyses en wist  je  voor extra diepgang  te 








onderzoeksproject.  Samen  hebben  we  onze  data  mogen  presenteren  bij  het 







Mijn dankwoord, de plek om eenieder te bedanken die belangrijk voor mij is geweest 
tijdens de totstandkoming van dit boekje en ver daarbuiten.  
 
Ten eerste was mijn proefschrift nooit tot stand gekomen zonder de deelnemende 
kinderen. Ik heb genoten van de inzet en trotse gezichten van de 5- en 8-jarige 
kinderen tijdens de onderzoeksdagen in het ziekenhuis en bij de kinderen thuis. 
Sommige kinderen vonden het spannend, anderen kletsten aan een stuk door. We 
hebben heel veel mooie tekeningen mogen ontvangen. Ook de ouders en leraren van 
de deelnemende kinderen wil ik bedanken voor het (soms urenlang) invullen van onze 
vragenlijsten. Net als de kinderen waren de deelnemende ouders ontzettend 
enthousiast en natuurlijk trots als een pauw wanneer hun kind, veelal met stralende 
glimlach, de onderzoekskamer uit kwam. Tevens hebben deze ouders mij onbewust 
gevormd tot de klinisch geneticus die ik nu ben, door hun verhaal met mij te delen 
over de impact van de erfelijke aandoening op hun gezin en in het dagelijks leven. 
Vele foto’s van hun dierbare aangedane kinderen of andere familieleden heb ik 
mogen bewonderen. Dit heeft een speciale diepgang in mijn kennis over genetica en 
erfelijkheid gebracht, een diepgang die niet in studieboeken te vinden is. Deze mooie 
en ontroerende verhalen hebben mij gedurende het gehele traject gemotiveerd om 
dit proefschrift vorm te geven. 
 
Natuurlijk wil ik ook graag mijn promotor en copromotoren bedanken. Prof. dr. 
Christine de Die-Smulders, beste Christine, ik kan me het moment nog herinneren 
waarop ik jou vertelde dat ik graag zou willen promoveren. Je was totaal niet verrast, 
maar juist in afwachting van dit besluit. Deze reactie tekent jou, je hebt oog voor 
iemands professionele ontwikkeling maar ook voor de persoon achter de professional. 
Jij begrijpt dat privé en werk soms in elkaar overvloeien en gaf mij de ruimte om 
daarmee om te leren gaan. Je bent kritisch en weet mij altijd te stimuleren om de 
zogenaamde puntjes op de i te zetten. Ook als klinisch geneticus kan ik veel van je 
leren, want tijdens het onderzoek heb ik gemerkt hoeveel waardering de ouders voor 
jou als dokter hebben. Menig vriendelijke groet kreeg je van de ouders die wij zagen! 
De huidige corona-situatie heeft ons werk erg veranderd waardoor we elkaar helaas 















Pap  en  mam,  voor  jullie  kom  ik  woorden  te  kort.  Jullie  hebben  mij  normen  en 
waarden bijgebracht en  geleerd wat doorzettingsvermogen  is. Welke  keuzes  ik ook 




Stan en  Julia, we komen uit hetzelfde nest, maar  zijn  zo verschillend. Stan,  jij  staat 
altijd met beide benen op de grond en geniet van het  leven met Maddy en de kids. 
Stiekem  heb  ik  al  heel  veel  opvoedtrucjes  van mijn  kleine  broertje  (en  schoonzus) 
afgekeken.  Zo  leuk  om  te  zien  hoe  jij  van  rebelse  puber  tot  liefdevolle  partner  en 
vader bent uitgegroeid!  Juul,  jij ontdekt, ervaart, analyseert en  fantaseert erop  los. 
Jouw artistieke leven is niet aan mij besteed maar ik heb er des te meer bewondering 
voor! Heerlijk om te zien hoe  jij  jezelf bent, daar kan menig mens van  leren! Ik weet 
zeker  dat  je  een  prachtige  en wonderlijke  toekomst  tegemoet  gaat. Natuurlijk  ook 
bedankt voor de mooie illustratie voor de kaft van dit proefschrift. 
 
Lieve Giel,  je brengt rust en stabiliteit en vooral ook heel veel  liefde  in mijn  leven. Ik 
geniet ontzettend  van het dorpse, misschien  volgens anderen wel burgerlijke  leven 
met  jou  en  onze  twee  schatten  van meiden. We  zijn  ontzettend  snel  van  verliefd 
stelletje  naar  samenwonend,  en  vervolgens  ‘ouders  van’  gegaan,  en  genieten met 
volle  teugen  van  elke  nieuwe  stap  in  ons  leven.  Loïs  en  Ella,  onze  twee  kleine 











gebouw  als  tijdens  congressen  en/of  cursussen.  Onze  verschillende manieren  van 
werken  hebben  ervoor  gezorgd  dat we  veel  van  elkaar  konden  leren.  Jij  hebt mij 
meerdere  malen  een  spiegel  voorgehouden  en  liet  mij  dingen  vanuit  een  ander 
perspectief  bekijken.  Naast  hard  werken  was  er  natuurlijk  genoeg  tijd  voor  een 
gezellig praatje, waardoor er al  snel een  vriendschap  is ontstaan. Helaas  voor onze 
afdeling heb  jij besloten om een ander carrière pad te bewandelen, een keuze die  ik 





ieder  onze  eigen  droombaan,  een  lieve  partner  en  2  kids  om  trots  op  te  zijn  én 
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enthousiast en natuurlijk trots als een pauw wanneer hun kind, veelal met stralende 
glimlach, de onderzoekskamer uit kwam. Tevens hebben deze ouders mij onbewust 
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over de impact van de erfelijke aandoening op hun gezin en in het dagelijks leven. 
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en ontroerende verhalen hebben mij gedurende het gehele traject gemotiveerd om 
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waarop ik jou vertelde dat ik graag zou willen promoveren. Je was totaal niet verrast, 
maar juist in afwachting van dit besluit. Deze reactie tekent jou, je hebt oog voor 
iemands professionele ontwikkeling maar ook voor de persoon achter de professional. 
Jij begrijpt dat privé en werk soms in elkaar overvloeien en gaf mij de ruimte om 
daarmee om te leren gaan. Je bent kritisch en weet mij altijd te stimuleren om de 
zogenaamde puntjes op de i te zetten. Ook als klinisch geneticus kan ik veel van je 
leren, want tijdens het onderzoek heb ik gemerkt hoeveel waardering de ouders voor 
jou als dokter hebben. Menig vriendelijke groet kreeg je van de ouders die wij zagen! 
De huidige corona-situatie heeft ons werk erg veranderd waardoor we elkaar helaas 




































Venlo,  alwaar  zij  in  2006 haar diploma mocht ontvangen. Het daaropvolgende  jaar 
startte  zij met de opleiding  tot HBO Verpleegkundige  aan de  Fontys Hogeschool  te 




Genetica  al  vroeg  gewekt.  In  het  vierde  jaar  van  haar  opleiding  koos  zij  voor  een 
algemene  keuzestage  bij  de  afdeling  Klinische  Genetica  in Maastricht.  Dit was  het 
eerste  contact  met  haar  promotor  Prof.  dr.  C.E.M.  de  Die‐Smulders.  Onder 
begeleiding  van  Prof.  dr. C.E.M.  de Die‐Smulders participeerde  zij  in het  kader  van 
haar wetenschappelijke stage in een studie naar de vruchtbaarheid van vrouwen met 
een mutatie  in  het  BRCA1  of  BRCA2  gen.  Het  laatste  deel  van  haar  geneeskunde 
opleiding  bestond  uit  een  klinische  stage  bij  de  afdeling  Klinische  Genetica  in 
Maastricht. Tijdens deze stage  lag de  focus op de  reproductieve genetica waarbij zij 
werd begeleid door haar latere opleider en co‐promotor dr. Y.H.J.M. Arens.  
Aansluitend aan haar geneeskunde opleiding startte Malou  in 2013 met de opleiding 
tot  klinisch  geneticus.  In hetzelfde  jaar begon  zij ook met haar promotieonderzoek 
onder begeleiding van eerder genoemden en haar tweede co‐promotor dr. A.P.A. van 
Montfoort.  Dit  onderzoek  werd  gesubsidieerd  door  ZonMw  en  zij  ontving  een 
persoonlijke beurs van het Academisch Fonds, MUMC+. In lijn met dit promotietraject 
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